Pendahuluan
Halaman ini memberikan analisis komprehensif tentang sejarah perdagangan orang dalam yang diketahui dari Management Co Deerfield. Orang dalam adalah pejabat, direktur, atau investor signifikan dalam suatu perusahaan. Adalah ilegal bagi orang dalam untuk melakukan perdagangan di perusahaan mereka berdasarkan informasi spesifik yang tidak dipublikasikan. Ini tidak berarti bahwa mereka dilarang melakukan perdagangan apa pun di perusahaan mereka sendiri. Namun, mereka harus melaporkan semua perdagangan kepada SEC melalui Formulir 4. Terlepas dari pembatasan ini, penelitian akademis menunjukkan bahwa orang dalam - secara umum - cenderung mengungguli pasar di perusahaan mereka sendiri.
Rata-rata Profitabilitas Perdagangan
Profitabilitas perdagangan rata-rata adalah pengembalian rata-rata dari semua pembelian pasar terbuka yang dilakukan oleh orang dalam dalam tiga tahun terakhir. Untuk menghitung ini, kami memeriksa setiap pembelian pasar terbuka yang tidak direncanakan yang dilakukan oleh orang dalam, tidak termasuk semua perdagangan yang ditandai sebagai bagian dari rencana perdagangan 10b5-1. Kami kemudian menghitung kinerja rata-rata dari perdagangan tersebut selama 3, 6, dan 12 bulan, dengan merata-ratakan setiap durasi tersebut untuk menghasilkan metrik kinerja akhir untuk setiap perdagangan. Terakhir, kami merata-ratakan semua metrik kinerja untuk menghitung metrik kinerja untuk orang dalam. Daftar ini hanya mencakup orang dalam yang telah melakukan setidaknya tiga perdagangan dalam dua tahun terakhir.
Jika profitabilitas perdagangan orang dalam ini adalah "N/A", maka orang dalam tersebut belum melakukan pembelian di pasar terbuka dalam tiga tahun terakhir, atau perdagangan yang mereka lakukan terlalu baru untuk menghitung metrik kinerja yang andal.
Frekuensi Pembaruan: Setiap Hari
Lihat daftar pedagang dalam perusahaan yang paling menguntungkan.
Perusahaan dengan Posisi Orang Dalam yang Dilaporkan
Pengajuan SEC menunjukkan bahwa Management Co Deerfield telah melaporkan kepemilikan atau perdagangan di perusahaan-perusahaan berikut:
Cara Membaca Grafik
Grafik berikut menunjukkan kinerja saham sekuritas setelah setiap perdagangan pasar terbuka yang tidak direncanakan yang dilakukan oleh Management Co Deerfield. Perdagangan yang tidak direncanakan adalah perdagangan yang tidak dilakukan sebagai bagian dari rencana perdagangan 10b5-1. Kinerja saham digambarkan sebagai perubahan persentase kumulatif dalam harga saham. Misalnya, jika perdagangan orang dalam dilakukan pada 1 Januari 2019, grafik akan menunjukkan perubahan persentase harian sekuritas hingga saat ini. Jika harga saham naik dari $10 menjadi $15 selama periode ini, perubahan persentase kumulatif dalam harga saham akan menjadi 50%. Perubahan harga dari $10 menjadi $20 akan menjadi 100%, dan perubahan harga dari $10 menjadi $5 akan menjadi -50%.
Pada akhirnya, kita mencoba menentukan seberapa erat korelasi perdagangan orang dalam dengan pengembalian berlebih (positif atau negatif) pada harga saham untuk melihat apakah orang dalam tersebut mengatur waktu perdagangannya untuk mendapatkan keuntungan dari informasi orang dalam. Pertimbangkan situasi di mana orang dalam melakukan hal ini. Dalam situasi ini, kita akan mengharapkan (a) pengembalian positif setelah pembelian, atau (b) pengembalian negatif setelah penjualan. Dalam kasus (a), grafik PEMBELIAN akan menunjukkan serangkaian kurva yang miring ke atas, menunjukkan pengembalian positif setelah setiap transaksi pembelian. Dalam kasus (b), grafik PENJUALAN akan menunjukkan serangkaian kurva yang miring ke bawah, menunjukkan pengembalian negatif setelah setiap transaksi penjualan.
Namun, ini saja tidak cukup untuk menarik kesimpulan. Jika, misalnya, harga saham perusahaan berada dalam tren kenaikan non-siklikal selama bertahun-tahun, maka kita akan mengharapkan semua plot pasca-pembelian memiliki kemiringan ke atas. Demikian pula, penurunan non-siklikal selama bertahun-tahun akan menghasilkan plot pasca-perdagangan dengan kemiringan ke bawah. Tak satu pun dari grafik ini akan menunjukkan aktivitas perdagangan orang dalam.
Indikator terkuat adalah situasi di mana harga saham sangat siklikal, dan terdapat sinyal positif pada grafik PEMBELIAN dan plot negatif pada grafik PENJUALAN. Situasi ini akan sangat menunjukkan adanya orang dalam yang mengatur waktu perdagangan untuk keuntungan finansial mereka.
Pembelian Orang Dalam ACRS / Aclaris Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam ACRS / Aclaris Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam ADVM / Adverum Biotechnologies, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam ADVM / Adverum Biotechnologies, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam AFIB / Acutus Medical, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam AFIB / Acutus Medical, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam AHCO / AdaptHealth Corp. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2018-02-21 | DFBH | Flynn James E | 2,500,000 | 2,500,000 | 266 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam AHCO / AdaptHealth Corp. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam AIS / Tidal Trust III - VistaShares Artificial Intelligence Supercycle ETF - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam AIS / Tidal Trust III - VistaShares Artificial Intelligence Supercycle ETF - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam ANNX / Annexon, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam ANNX / Annexon, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam ARVN / Arvinas, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam ARVN / Arvinas, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam ATYR / aTyr Pharma, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam ATYR / aTyr Pharma, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam AVDL / Avadel Pharmaceuticals plc - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam AVDL / Avadel Pharmaceuticals plc - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2018-06-25 | AVDL | Flynn James E | 114,034 | 5.9922 | 114,034 | 5.9922 | 683,315 | 304 | 1.0900 | -559,017 | -81.81 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam AXGN / Axogen, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam AXGN / Axogen, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam BDTX / Black Diamond Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2020-02-03 | BDTX | Flynn James E | 400,000 | 19.0000 | 400,000 | 19.0000 | 7,600,000 | 140 | 44.8 | 10,320,000 | 135.79 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam BDTX / Black Diamond Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam BOLD / Boundless Bio, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam BOLD / Boundless Bio, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam CABA / Cabaletta Bio, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2019-10-29 | CABA | Flynn James E | 700,000 | 11.0000 | 700,000 | 11.0000 | 7,700,000 | 92 | 18.67 | 5,369,000 | 69.73 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam CABA / Cabaletta Bio, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam CALC / CalciMedica, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2020-09-29 | GRAY | Flynn James E | 1,562,500 | 16.0000 | 111,607 | 224.0000 | 25,000,000 | 115 | 490 | 29,687,430 | 118.75 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam CALC / CalciMedica, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam CTMX / CytomX Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam CTMX / CytomX Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam CYCCP / Cyclacel Pharmaceuticals, Inc. - Preferred Stock - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam CYCCP / Cyclacel Pharmaceuticals, Inc. - Preferred Stock - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam EDIT / Editas Medicine, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2016-02-08 | EDIT | Flynn James E | 100,000 | 16.0000 | 100,000 | 16.0000 | 1,600,000 | 57 | 42.0400 | 2,604,000 | 162.75 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam EDIT / Editas Medicine, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam EHTH / eHealth, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam EHTH / eHealth, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam EWTX / Edgewise Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2021-03-30 | EWTX | Flynn James E | 625,000 | 16.0000 | 625,000 | 16.0000 | 10,000,000 | 1 | 32.5 | 10,312,500 | 103.12 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam EWTX / Edgewise Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam GBIO / Generation Bio Co. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2020-06-16 | GBIO | Flynn James E | 225,000 | 19.0000 | 22,500 | 190.0000 | 4,275,000 | 169 | 51.61 | -3,113,775 | -72.84 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam GBIO / Generation Bio Co. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam GUTS / Fractyl Health, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam GUTS / Fractyl Health, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam HOWL / Werewolf Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2021-05-04 | HOWL | Flynn James E | 800,000 | 16.0000 | 800,000 | 16.0000 | 12,800,000 | 59 | 20.3100 | 3,448,000 | 26.94 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam HOWL / Werewolf Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam KNSA / Kiniksa Pharmaceuticals, Ltd. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam KNSA / Kiniksa Pharmaceuticals, Ltd. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam KRRO / Korro Bio, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2019-10-07 | FREQ | Flynn James E | 285,714 | 14.0000 | 285,714 | 14.0000 | 3,999,996 | 121 | 27.55 | 3,871,425 | 96.79 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam KRRO / Korro Bio, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam LRMR / Larimar Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam LRMR / Larimar Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam MIRM / Mirum Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam MIRM / Mirum Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam NKTX / Nkarta, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam NKTX / Nkarta, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam NUVL / Nuvalent, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam NUVL / Nuvalent, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam PEPG / PepGen Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam PEPG / PepGen Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam PHGE / BiomX Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam PHGE / BiomX Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam QTTB / Q32 Bio Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam QTTB / Q32 Bio Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam RGNX / REGENXBIO Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam RGNX / REGENXBIO Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam RIGL / Rigel Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam RIGL / Rigel Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam RVMD / Revolution Medicines, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam RVMD / Revolution Medicines, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam RYTM / Rhythm Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam RYTM / Rhythm Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam SDGR / Schrödinger, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2020-02-10 | SDGR | Flynn James E | 250,000 | 17.0000 | 250,000 | 17.0000 | 4,250,000 | 365 | 105.46 | 22,115,000 | 520.35 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam SDGR / Schrödinger, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam SPRY / ARS Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam SPRY / ARS Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam SYRS / Syros Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam SYRS / Syros Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam TARA / Protara Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam TARA / Protara Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2017-11-30 | PRTO | Flynn James E | 110,557 | 1.7500 | 110,557 | 1.7500 | 193,475 | 312 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam TERN / Terns Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2021-02-09 | TERN | Flynn James E | 665,000 | 17.0000 | 665,000 | 17.0000 | 11,305,000 | 38 | 27.25 | 6,816,250 | 60.29 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam TERN / Terns Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam VNDA / Vanda Pharmaceuticals Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam VNDA / Vanda Pharmaceuticals Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam XLO / Xilio Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam XLO / Xilio Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRS / Aclaris Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Sejarah Perdagangan Orang Dalam
Tabel ini menunjukkan daftar lengkap transaksi orang dalam yang dilakukan oleh Management Co Deerfield sebagaimana diungkapkan kepada Komisi Bursa Efek (Securities Exchange Commission/SEC).
Tanggal File | Tanggal Transaksi | Formulir | Ticker | Keamanan | Kode | Saham | Sisa Saham | Persen Ubah |
Bagikan Harga |
Tran Nilai |
Sisa Nilai |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-04 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 2,599,932 | 7,321,129 | 55.07 | 3.20 | 8,319,782 | 23,427,613 | |
2025-08-04 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 3,387,539 | 9,538,945 | 55.07 | 3.20 | 10,840,125 | 30,524,624 | |
2025-08-04 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 3,387,529 | 9,538,918 | 55.07 | 3.20 | 10,840,093 | 30,524,538 | |
2025-07-01 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Class A Common Stock |
S - Sale | -370,074 | 4,887,254 | -7.04 | 18.46 | -6,831,566 | 90,218,709 | |
2025-07-01 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Class A Common Stock |
S - Sale | -370,075 | 4,887,254 | -7.04 | 18.46 | -6,831,584 | 90,218,709 | |
2025-06-20 |
|
4 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
A - Award | 2,647 | 2,647 | |||||
2025-06-20 |
|
4 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
A - Award | 2,647 | 2,647 | |||||
2025-03-03 |
|
4 | PHGE |
BiomX Inc.
Common Stock |
M - Exercise | 353,249 | 1,247,054 | 39.52 | 0.93 | 328,734 | 1,160,508 | |
2025-03-03 |
|
4 | PHGE |
BiomX Inc.
Common Stock |
M - Exercise | 353,249 | 1,247,054 | 39.52 | 0.93 | 328,734 | 1,160,508 | |
2024-11-13 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Class A Common Stock |
S - Sale | -9,553 | 5,257,328 | -0.18 | 17.77 | -169,757 | 93,422,719 | |
2024-11-13 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Class A Common Stock |
S - Sale | -9,554 | 5,257,329 | -0.18 | 17.77 | -169,775 | 93,422,736 | |
2024-11-13 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Class A Common Stock |
S - Sale | -7,854 | 5,266,881 | -0.15 | 17.16 | -134,775 | 90,379,678 | |
2024-11-13 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Class A Common Stock |
S - Sale | -7,853 | 5,266,883 | -0.15 | 17.16 | -134,757 | 90,379,712 | |
2024-11-13 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Class A Common Stock |
S - Sale | -223,632 | 5,274,735 | -4.07 | 18.15 | -4,058,921 | 95,736,440 | |
2024-11-13 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Class A Common Stock |
S - Sale | -223,632 | 5,274,735 | -4.07 | 18.15 | -4,058,921 | 95,736,440 | |
2024-11-13 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Class A Common Stock |
S - Sale | -40,596 | 5,498,367 | -0.73 | 17.45 | -708,400 | 95,946,504 | |
2024-11-13 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Class A Common Stock |
S - Sale | -40,596 | 5,498,367 | -0.73 | 17.45 | -708,400 | 95,946,504 | |
2024-10-24 |
|
4 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
S - Sale | -1,000,000 | 8,670,512 | -10.34 | 97.75 | -97,750,000 | 847,542,548 | |
2024-10-24 |
|
4 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
S - Sale | -1,000,000 | 8,670,512 | -10.34 | 97.75 | -97,750,000 | 847,542,548 | |
2024-09-17 |
|
4 | BCAX |
Bicara Therapeutics Inc.
Common Stock |
P - Purchase | 35,000 | 897,587 | 4.06 | 18.00 | 630,000 | 16,156,566 | |
2024-09-17 |
|
4 | BCAX |
Bicara Therapeutics Inc.
Common Stock |
P - Purchase | 35,000 | 897,587 | 4.06 | 18.00 | 630,000 | 16,156,566 | |
2024-09-17 |
|
4 | BCAX |
Bicara Therapeutics Inc.
Common Stock |
C - Conversion | 862,587 | 862,587 | |||||
2024-09-17 |
|
4 | BCAX |
Bicara Therapeutics Inc.
Common Stock |
C - Conversion | 862,587 | 862,587 | |||||
2024-07-17 |
|
4 | PHGE |
BiomX Inc.
Common Stock |
M - Exercise | 5,883,000 | 8,938,049 | 192.57 | ||||
2024-07-17 |
|
4 | PHGE |
BiomX Inc.
Common Stock |
M - Exercise | 5,883,000 | 8,938,049 | 192.57 | ||||
2024-06-14 |
|
4 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
A - Award | 2,499 | 2,499 | |||||
2024-06-14 |
|
4 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
A - Award | 2,499 | 2,499 | |||||
2024-03-19 |
|
4 | PHGE |
BiomX Inc.
Common Stock |
A - Award | 3,055,049 | 3,055,049 | |||||
2024-03-19 |
|
4 | PHGE |
BiomX Inc.
Common Stock |
A - Award | 3,055,049 | 3,055,049 | |||||
2024-03-12 |
|
4 | AHCO |
AdaptHealth Corp.
Class A Common Stock |
S - Sale | -114,906 | 11,528,863 | -0.99 | 10.70 | -1,229,494 | 123,358,834 | |
2024-03-12 |
|
4 | AHCO |
AdaptHealth Corp.
Class A Common Stock |
S - Sale | -88,040 | 11,643,769 | -0.75 | 11.13 | -979,885 | 129,595,149 | |
2024-03-12 |
|
4 | AHCO |
AdaptHealth Corp.
Class A Common Stock |
S - Sale | -94,567 | 11,731,809 | -0.80 | 10.92 | -1,032,672 | 128,111,354 | |
2024-03-12 |
|
4 | AHCO |
AdaptHealth Corp.
Class A Common Stock |
S - Sale | -4,495 | 11,826,376 | -0.04 | 11.03 | -49,580 | 130,444,927 | |
2024-03-12 |
|
4 | AHCO |
AdaptHealth Corp.
Class A Common Stock |
S - Sale | -47,992 | 11,830,871 | -0.40 | 10.92 | -524,073 | 129,193,111 | |
2024-03-08 | 3 | AHCO |
AdaptHealth Corp.
Class A Common Stock |
11,878,863 | ||||||||
2024-03-08 | 3 | AHCO |
AdaptHealth Corp.
Class A Common Stock |
1,709,077 | ||||||||
2024-03-08 | 3 | AHCO |
AdaptHealth Corp.
Class A Common Stock |
20,000 | ||||||||
2024-02-16 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 1,430,205 | 4,207,982 | 51.49 | 8.74 | 12,499,992 | 36,777,763 | |
2024-02-16 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 1,430,206 | 6,151,406 | 30.29 | 8.74 | 12,500,000 | 53,763,288 | |
2024-02-16 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 1,430,206 | 6,151,406 | 30.29 | 8.74 | 12,500,000 | 53,763,288 | |
2024-02-08 |
|
4 | GUTS |
Fractyl Health, Inc.
Common Stock |
C - Conversion | 76,706 | 834,254 | 10.13 | ||||
2024-02-08 |
|
4 | GUTS |
Fractyl Health, Inc.
Common Stock |
C - Conversion | 757,548 | 757,548 | |||||
2023-11-21 |
|
4 | CMAX |
CareMax, Inc.
Class A Common Stock |
M - Exercise | 12,123 | 12,123 | |||||
2023-08-01 |
|
4 | DALS |
DA32 Life Science Tech Acquisition Corp.
Class A Common Stock |
J - Other | -1,600,000 | 0 | -100.00 | ||||
2023-06-20 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
A - Award | 8,400 | 20,822 | 67.62 | ||||
2023-06-20 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
A - Award | 8,400 | 12,422 | 208.85 | ||||
2022-12-30 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -15,220 | 284,697 | -5.07 | 0.27 | -4,109 | 76,868 | |
2022-12-30 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -61,826 | 1,156,308 | -5.08 | 0.27 | -16,693 | 312,203 | |
2022-12-30 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -61,826 | 1,156,308 | -5.08 | 0.27 | -16,693 | 312,203 | |
2022-12-30 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -15,538 | 299,917 | -4.93 | 0.26 | -4,040 | 77,978 | |
2022-12-30 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -63,108 | 1,218,134 | -4.93 | 0.26 | -16,408 | 316,715 | |
2022-12-30 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -63,107 | 1,218,135 | -4.93 | 0.26 | -16,408 | 316,715 | |
2022-12-30 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -6,096 | 315,455 | -1.90 | 0.25 | -1,524 | 78,864 | |
2022-12-30 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -24,757 | 1,281,242 | -1.90 | 0.25 | -6,189 | 320,310 | |
2022-12-30 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -24,757 | 1,281,242 | -1.90 | 0.25 | -6,189 | 320,310 | |
2022-12-27 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -7,136 | 321,551 | -2.17 | 0.27 | -1,927 | 86,819 | |
2022-12-27 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -28,977 | 1,305,999 | -2.17 | 0.27 | -7,824 | 352,620 | |
2022-12-27 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -28,977 | 1,305,999 | -2.17 | 0.27 | -7,824 | 352,620 | |
2022-12-27 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -909 | 328,687 | -0.28 | 0.28 | -255 | 92,032 | |
2022-12-27 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -3,693 | 1,334,976 | -0.28 | 0.28 | -1,034 | 373,793 | |
2022-12-27 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -3,692 | 1,334,976 | -0.28 | 0.28 | -1,034 | 373,793 | |
2022-12-21 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -1,513 | 329,596 | -0.46 | 0.30 | -454 | 98,879 | |
2022-12-21 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -6,143 | 1,338,669 | -0.46 | 0.30 | -1,843 | 401,601 | |
2022-12-21 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -6,144 | 1,338,668 | -0.46 | 0.30 | -1,843 | 401,600 | |
2022-12-21 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -1,616 | 331,109 | -0.49 | 0.31 | -501 | 102,644 | |
2022-12-21 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -6,562 | 1,344,812 | -0.49 | 0.31 | -2,034 | 416,892 | |
2022-12-21 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -6,562 | 1,344,812 | -0.49 | 0.31 | -2,034 | 416,892 | |
2022-12-21 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -10,930 | 332,725 | -3.18 | 0.29 | -3,170 | 96,490 | |
2022-12-21 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -44,394 | 1,351,374 | -3.18 | 0.29 | -12,874 | 391,898 | |
2022-12-21 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -44,394 | 1,351,374 | -3.18 | 0.29 | -12,874 | 391,898 | |
2022-12-15 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -339 | 343,655 | -0.10 | 0.39 | -132 | 134,025 | |
2022-12-15 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -1,375 | 1,395,768 | -0.10 | 0.39 | -536 | 544,350 | |
2022-12-15 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -1,375 | 1,395,768 | -0.10 | 0.39 | -536 | 544,350 | |
2022-12-15 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -943 | 343,994 | -0.27 | 0.38 | -358 | 130,718 | |
2022-12-15 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -3,829 | 1,397,143 | -0.27 | 0.38 | -1,455 | 530,914 | |
2022-12-15 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -3,828 | 1,397,143 | -0.27 | 0.38 | -1,455 | 530,914 | |
2022-12-15 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -230 | 344,937 | -0.07 | 0.41 | -94 | 141,424 | |
2022-12-15 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -933 | 1,400,972 | -0.07 | 0.41 | -383 | 574,399 | |
2022-12-15 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -934 | 1,400,971 | -0.07 | 0.41 | -383 | 574,398 | |
2022-11-14 | 3 | FLAC |
Frazier Lifesciences Acquisition Corp
Class A Ordinary Shares |
2,480,199 | ||||||||
2022-11-10 | 3 | SPRY |
ARS Pharmaceuticals, Inc.
Common Stock |
5,538,964 | ||||||||
2022-11-10 | 3 | SPRY |
ARS Pharmaceuticals, Inc.
Common stock |
5,538,964 | ||||||||
2022-11-07 |
|
4 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
P - Purchase | 650,000 | 650,000 | 33.50 | 21,775,000 | 21,775,000 | ||
2022-09-20 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 2,777,777 | 2,777,777 | 3.15 | 8,749,998 | 8,749,998 | ||
2022-09-20 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 2,777,777 | 2,777,777 | 3.15 | 8,749,998 | 8,749,998 | ||
2022-09-20 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 2,777,777 | 2,777,777 | 3.15 | 8,749,998 | 8,749,998 | ||
2022-09-20 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 2,777,777 | 2,777,777 | 3.15 | 8,749,998 | 8,749,998 | ||
2022-06-08 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
S - Sale | -6,243 | 1,540,190 | -0.40 | 24.47 | -152,766 | 37,688,449 | |
2022-06-08 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
S - Sale | -6,909 | 1,704,244 | -0.40 | 24.47 | -169,063 | 41,702,851 | |
2022-06-08 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
S - Sale | -155 | 1,546,433 | -0.01 | 25.08 | -3,887 | 38,784,540 | |
2022-06-08 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
S - Sale | -171 | 1,711,153 | -0.01 | 25.08 | -4,289 | 42,915,717 | |
2022-06-08 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
S - Sale | -11,868 | 1,546,588 | -0.76 | 25.29 | -300,142 | 39,113,211 | |
2022-06-08 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
S - Sale | -13,132 | 1,711,324 | -0.76 | 25.29 | -332,108 | 43,279,384 | |
2022-05-11 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 8,300 | 8,300 | |||||
2022-05-10 |
|
4 | PEPG |
PepGen Inc.
Series B Preferred Stock |
C - Conversion | -273,313 | 0 | -100.00 | ||||
2022-05-10 |
|
4 | PEPG |
PepGen Inc.
Series B Preferred Stock |
C - Conversion | -273,313 | 0 | -100.00 | ||||
2022-05-10 |
|
4 | PEPG |
PepGen Inc.
Common Stock |
P - Purchase | 208,333 | 476,813 | 77.60 | 12.00 | 2,499,996 | 5,721,756 | |
2022-05-10 |
|
4 | PEPG |
PepGen Inc.
Common Stock |
P - Purchase | 208,333 | 476,813 | 77.60 | 12.00 | 2,499,996 | 5,721,756 | |
2022-05-10 |
|
4 | PEPG |
PepGen Inc.
Common Stock |
C - Conversion | 268,480 | 268,480 | |||||
2022-05-10 |
|
4 | PEPG |
PepGen Inc.
Common Stock |
C - Conversion | 268,480 | 268,480 | |||||
2021-11-16 |
|
4 | DFPH |
Oncology Institute, Inc.
Public Warrants |
J - Other | 625,000 | 625,000 | |||||
2021-11-16 |
|
4 | DFPH |
Oncology Institute, Inc.
Public Warrants |
J - Other | 625,000 | 625,000 | |||||
2021-11-16 |
|
4 | DFPH |
Oncology Institute, Inc.
Private Placement Warrants |
J - Other | 3,177,543 | 3,177,543 | |||||
2021-11-16 |
|
4 | DFPH |
Oncology Institute, Inc.
Class B Common Stock |
C - Conversion | -85,113 | 0 | -100.00 | ||||
2021-11-16 |
|
4 | DFPH |
Oncology Institute, Inc.
Class B Common Stock |
C - Conversion | -40 | 0 | -100.00 | ||||
2021-11-16 |
|
4 | DFPH |
Oncology Institute, Inc.
Class B Common Stock |
J - Other | -14,887 | 85,113 | -14.89 | ||||
2021-11-16 |
|
4 | DFPH |
Oncology Institute, Inc.
Class B Common Stock |
J - Other | -707,960 | 40 | -99.99 | ||||
2021-11-16 |
|
4 | DFPH |
Oncology Institute, Inc.
Series A Common Stock Equivalent Convertible Preferred Stock |
P - Purchase | 50,000 | 58,945 | 558.97 | 1,000.00 | 50,000,000 | 58,945,000 | |
2021-11-16 |
|
4 | DFPH |
Oncology Institute, Inc.
Series A Common Stock Equivalent Convertible Preferred Stock |
P - Purchase | 50,000 | 58,945 | 558.97 | 1,000.00 | 50,000,000 | 58,945,000 | |
2021-11-16 |
|
4 | DFPH |
Oncology Institute, Inc.
Class A Common Stock |
C - Conversion | 85,113 | 85,113 | |||||
2021-11-16 |
|
4 | DFPH |
Oncology Institute, Inc.
Class A Common Stock |
C - Conversion | 40 | 40 | |||||
2021-10-28 |
|
4 | XLO |
Xilio Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -7,186,489 | 0 | -100.00 | ||||
2021-10-28 |
|
4 | XLO |
Xilio Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -7,186,489 | 0 | -100.00 | ||||
2021-10-28 |
|
4 | XLO |
Xilio Therapeutics, Inc.
Common Stock |
P - Purchase | 387,500 | 1,143,972 | 51.22 | 16.00 | 6,200,000 | 18,303,552 | |
2021-10-28 |
|
4 | XLO |
Xilio Therapeutics, Inc.
Common Stock |
P - Purchase | 387,500 | 1,143,972 | 51.22 | 16.00 | 6,200,000 | 18,303,552 | |
2021-10-28 |
|
4 | XLO |
Xilio Therapeutics, Inc.
Common Stock |
C - Conversion | 756,472 | 756,472 | |||||
2021-10-28 |
|
4 | XLO |
Xilio Therapeutics, Inc.
Common Stock |
C - Conversion | 756,472 | 756,472 | |||||
2021-09-02 |
|
4 | AFIB |
Acutus Medical, Inc.
Stock Option (Right to Buy) |
A - Award | 7,022 | 7,022 | |||||
2021-09-02 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
A - Award | 1,800 | 4,022 | 81.01 | ||||
2021-08-09 |
|
4 | DALS |
DA32 Life Science Tech Acquisition Corp.
Class B Common Stock, par value $0.0001 per share |
D - Sale to Issuer | -701,250 | 4,465,000 | -13.57 | ||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Class B Common Stock |
P - Purchase | 300,000 | 2,717,628 | 12.41 | 17.00 | 5,100,000 | 46,199,676 | |
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Class B Common Stock |
P - Purchase | 300,000 | 2,717,628 | 12.41 | 17.00 | 5,100,000 | 46,199,676 | |
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Class B Common Stock |
C - Conversion | 2,417,628 | 2,417,628 | |||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Class B Common Stock |
C - Conversion | 2,417,628 | 2,417,628 | |||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Series B Preferred Stock |
C - Conversion | -4,831,384 | 0 | -100.00 | ||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Series B Preferred Stock |
C - Conversion | -4,831,384 | 0 | -100.00 | ||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Series A Preferred Stock |
C - Conversion | -13,011,988 | 0 | -100.00 | ||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Series A Preferred Stock |
C - Conversion | -13,011,988 | 0 | -100.00 | ||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Series A Preferred Stock |
C - Conversion | -45,716,568 | 13,011,988 | -77.84 | ||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Series A Preferred Stock |
C - Conversion | -45,716,568 | 13,011,988 | -77.84 | ||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
C - Conversion | 897,671 | 9,670,511 | 10.23 | ||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
C - Conversion | 897,671 | 9,670,511 | 10.23 | ||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
C - Conversion | 8,494,140 | 8,772,840 | 3,047.77 | ||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
C - Conversion | 8,494,140 | 8,772,840 | 3,047.77 | ||||
2021-08-03 |
|
4 | DALS |
DA32 Life Science Tech Acquisition Corp.
Class A Common Stock |
A - Award | 650,000 | 2,250,000 | 40.62 | 10.00 | 6,500,000 | 22,500,000 | |
2021-08-03 |
|
4 | DALS |
DA32 Life Science Tech Acquisition Corp.
Class A Common Stock |
P - Purchase | 1,600,000 | 1,600,000 | 10.00 | 16,000,000 | 16,000,000 | ||
2021-07-30 |
|
4 | NUVL |
Nuvalent, Inc.
Stock Option (Right to Buy) |
A - Award | 43,000 | 43,000 | |||||
2021-07-30 |
|
4 | NUVL |
Nuvalent, Inc.
Stock Option (Right to Buy) |
A - Award | 43,000 | 43,000 | |||||
2021-07-28 | 3 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
278,700 | ||||||||
2021-07-28 | 3 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
278,700 | ||||||||
2021-07-21 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
P - Purchase | 680,592 | 3,438,589 | 24.68 | 14.00 | 9,528,288 | 48,140,246 | |
2021-07-21 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
P - Purchase | 390,836 | 1,974,638 | 24.68 | 14.00 | 5,471,704 | 27,644,932 | |
2021-07-13 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
S - Sale | -99,325 | 0 | -100.00 | 15.81 | -1,570,328 | ||
2021-07-07 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
S - Sale | -6,837 | 99,325 | -6.44 | 15.87 | -108,496 | 1,576,188 | |
2021-07-07 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
S - Sale | -49,239 | 106,162 | -31.69 | 16.20 | -797,426 | 1,719,294 | |
2021-07-07 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
S - Sale | -10,599 | 155,401 | -6.38 | 17.01 | -180,300 | 2,643,526 | |
2021-07-02 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 228,570 | 1,943,420 | 13.33 | 8.75 | 1,999,988 | 17,004,925 | |
2021-07-02 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 228,571 | 1,943,423 | 13.33 | 8.75 | 1,999,996 | 17,004,951 | |
2021-07-02 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 228,569 | 1,943,406 | 13.33 | 8.75 | 1,999,979 | 17,004,802 | |
2021-06-10 |
|
4 | CMAX |
Deerfield Healthcare Technology Acquisitions Corp.
Public Warrants |
J - Other | 672,000 | 672,000 | |||||
2021-06-10 |
|
4 | CMAX |
Deerfield Healthcare Technology Acquisitions Corp.
Private Placement Warrants |
A - Award | 2,916,667 | 2,916,667 | |||||
2021-06-10 |
|
4 | CMAX |
Deerfield Healthcare Technology Acquisitions Corp.
Class B common stock |
M - Exercise | -50,000 | 0 | -100.00 | ||||
2021-06-10 |
|
4 | CMAX |
Deerfield Healthcare Technology Acquisitions Corp.
Class B common stock |
M - Exercise | -3,368,750 | 0 | -100.00 | ||||
2021-06-10 |
|
4 | CMAX |
Deerfield Healthcare Technology Acquisitions Corp.
Class A common stock |
M - Exercise | 50,000 | 50,000 | |||||
2021-06-10 |
|
4 | CMAX |
Deerfield Healthcare Technology Acquisitions Corp.
Class A common stock |
M - Exercise | 3,368,750 | 3,768,750 | 842.19 | ||||
2021-06-10 |
|
4 | CMAX |
Deerfield Healthcare Technology Acquisitions Corp.
Class A common stock |
A - Award | 400,000 | 400,000 | 10.00 | 4,000,000 | 4,000,000 | ||
2021-06-10 |
|
4 | CMAX |
Deerfield Healthcare Technology Acquisitions Corp.
Class A common stock |
A - Award | 9,600,000 | 12,960,000 | 285.71 | 10.00 | 96,000,000 | 129,600,000 | |
2021-06-03 |
|
4 | OMIC |
Singular Genomics Systems, Inc.
6% Convertible Note due 2023 |
C - Conversion | 0 | ||||||
2021-06-03 |
|
4 | OMIC |
Singular Genomics Systems, Inc.
6% Convertible Note due 2023 |
C - Conversion | 0 | ||||||
2021-06-03 |
|
4 | OMIC |
Singular Genomics Systems, Inc.
Series B Preferred Stock |
C - Conversion | -6,457,723 | 0 | -100.00 | ||||
2021-06-03 |
|
4 | OMIC |
Singular Genomics Systems, Inc.
Common Stock |
P - Purchase | 1,050,000 | 1,627,148 | 181.93 | 22.00 | 23,100,000 | 35,797,256 | |
2021-06-03 |
|
4 | OMIC |
Singular Genomics Systems, Inc.
Common Stock |
P - Purchase | 450,000 | 7,484,871 | 6.40 | 22.00 | 9,900,000 | 164,667,162 | |
2021-06-03 |
|
4 | OMIC |
Singular Genomics Systems, Inc.
Common Stock |
C - Conversion | 577,148 | 577,148 | 17.60 | 10,157,805 | 10,157,805 | ||
2021-06-03 |
|
4 | OMIC |
Singular Genomics Systems, Inc.
Common Stock |
C - Conversion | 577,148 | 7,034,871 | 8.94 | 17.60 | 10,157,805 | 123,813,730 | |
2021-06-03 |
|
4 | OMIC |
Singular Genomics Systems, Inc.
Common Stock |
C - Conversion | 6,457,723 | 6,457,723 | |||||
2021-05-17 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 8,300 | 8,300 | |||||
2021-05-04 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -15,195,094 | 0 | -100.00 | ||||
2021-05-04 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
P - Purchase | 800,000 | 2,552,787 | 45.64 | 16.00 | 12,800,000 | 40,844,592 | |
2021-05-04 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
C - Conversion | 1,752,787 | 1,752,787 | |||||
2021-03-30 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -433,551 | 0 | -100.00 | ||||
2021-03-30 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -1,301,626 | 0 | -100.00 | ||||
2021-03-30 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Series B-1 Preferred Stock |
C - Conversion | -1,572,960 | 0 | -100.00 | ||||
2021-03-30 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Common Stock |
P - Purchase | 625,000 | 3,933,137 | 18.89 | 16.00 | 10,000,000 | 62,930,192 | |
2021-03-30 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Common Stock |
C - Conversion | 433,551 | 3,308,137 | 15.08 | ||||
2021-03-30 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Common Stock |
C - Conversion | 1,301,626 | 2,874,586 | 82.75 | ||||
2021-03-30 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Common Stock |
C - Conversion | 1,572,960 | 1,572,960 | |||||
2021-02-18 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
P - Purchase | 32,884 | 345,167 | 10.53 | 19.00 | 624,796 | 6,558,173 | |
2021-02-18 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
P - Purchase | 133,558 | 1,401,905 | 10.53 | 19.00 | 2,537,602 | 26,636,195 | |
2021-02-18 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
P - Purchase | 133,558 | 1,401,905 | 10.53 | 19.00 | 2,537,602 | 26,636,195 | |
2021-02-09 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Series C Preferred Stock |
C - Conversion | -1,717,033 | 0 | -100.00 | ||||
2021-02-09 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 665,000 | 2,382,033 | 38.73 | 17.00 | 11,305,000 | 40,494,561 | |
2021-02-09 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1,717,033 | 1,717,033 | |||||
2021-02-03 | 3 | IGNYU |
Ignyte Acquisition Corp.
Common Stock |
725,000 | ||||||||
2021-01-08 |
|
4 | LUMO |
LUMOS PHARMA, INC.
Common Stock |
S - Sale | -101,600 | 784,568 | -11.47 | 22.24 | -2,259,797 | 17,450,440 | |
2021-01-08 |
|
4 | LUMO |
LUMOS PHARMA, INC.
Common Stock |
S - Sale | -3,912 | 886,168 | -0.44 | 23.57 | -92,194 | 20,884,321 | |
2021-01-08 |
|
4 | LUMO |
LUMOS PHARMA, INC.
Common Stock |
S - Sale | -1,000 | 890,080 | -0.11 | 24.11 | -24,108 | 21,458,049 | |
2021-01-08 |
|
4 | LUMO |
LUMOS PHARMA, INC.
Common Stock |
S - Sale | -4,378 | 891,080 | -0.49 | 25.05 | -109,665 | 22,320,663 | |
2021-01-08 |
|
4 | LUMO |
LUMOS PHARMA, INC.
Common Stock |
S - Sale | -11,794 | 895,458 | -1.30 | 24.35 | -287,157 | 21,802,343 | |
2021-01-08 |
|
4 | LUMO |
LUMOS PHARMA, INC.
Common Stock |
S - Sale | -931 | 907,252 | -0.10 | 22.64 | -21,082 | 20,544,359 | |
2021-01-08 |
|
4 | LUMO |
LUMOS PHARMA, INC.
Common Stock |
S - Sale | -28,108 | 908,183 | -3.00 | 22.47 | -631,620 | 20,407,962 | |
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Series B Preferred Stock |
C - Conversion | -2,449,761 | 0 | -100.00 | ||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Series B Preferred Stock |
C - Conversion | -2,449,761 | 0 | -100.00 | ||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Series B Preferred Stock |
C - Conversion | -2,449,761 | 0 | -100.00 | ||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Series A-1 Preferred Stock |
C - Conversion | -7,499,999 | 0 | -100.00 | ||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Series A-1 Preferred Stock |
C - Conversion | -7,499,999 | 0 | -100.00 | ||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
P - Purchase | 109,612 | 312,282 | 54.08 | 15.00 | 1,644,180 | 4,684,230 | |
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
P - Purchase | 445,194 | 1,268,344 | 54.08 | 15.00 | 6,677,910 | 19,025,160 | |
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
P - Purchase | 445,194 | 1,268,344 | 54.08 | 15.00 | 6,677,910 | 19,025,160 | |
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
C - Conversion | 202,670 | 202,670 | |||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
C - Conversion | 202,670 | 202,670 | |||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
C - Conversion | 202,670 | 823,150 | 32.66 | ||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
C - Conversion | 620,480 | 620,480 | |||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
C - Conversion | 620,480 | 620,480 | |||||
2020-10-01 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 16,600 | 16,600 | |||||
2020-10-01 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Series C Preferred Stock |
C - Conversion | -2,624,901 | 0 | -100.00 | ||||
2020-10-01 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Series C Preferred Stock |
C - Conversion | -2,624,901 | 0 | -100.00 | ||||
2020-10-01 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Series C Preferred Stock |
C - Conversion | -2,624,901 | 0 | -100.00 | ||||
2020-10-01 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Series B Preferred Stock |
C - Conversion | -12,809,910 | 0 | -100.00 | ||||
2020-10-01 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Series B Preferred Stock |
C - Conversion | -12,809,912 | 0 | -100.00 | ||||
2020-10-01 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Common Stock |
P - Purchase | 1,562,500 | 1,853,967 | 536.08 | 16.00 | 25,000,000 | 29,663,472 | |
2020-10-01 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Common Stock |
C - Conversion | 291,467 | 291,467 | |||||
2020-10-01 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Common Stock |
C - Conversion | 291,467 | 291,467 | |||||
2020-10-01 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Common Stock |
C - Conversion | 291,467 | 291,467 | |||||
2020-10-01 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Common Stock |
C - Conversion | 1,422,406 | 1,422,406 | |||||
2020-10-01 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Common Stock |
C - Conversion | 1,422,406 | 1,422,406 | |||||
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Series D Preferred Stock |
C - Conversion | -1,002,464 | 0 | -100.00 | ||||
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Series D Preferred Stock |
C - Conversion | -189,366 | 0 | -100.00 | ||||
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Series C Preferred Stock |
C - Conversion | -1,199,980 | 0 | -100.00 | ||||
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Series C Preferred Stock |
C - Conversion | -449,992 | 0 | -100.00 | ||||
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
P - Purchase | 555,556 | 2,758,000 | 25.22 | 18.00 | 10,000,008 | 49,644,000 | |
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
P - Purchase | 944,444 | 1,583,802 | 147.72 | 18.00 | 16,999,992 | 28,508,436 | |
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
C - Conversion | 1,002,464 | 2,202,444 | 83.54 | ||||
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
C - Conversion | 189,366 | 639,358 | 42.08 | ||||
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
C - Conversion | 1,199,980 | 1,199,980 | |||||
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
C - Conversion | 449,992 | 449,992 | |||||
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Stock Options (Right to Buy) |
A - Award | 12,454 | 12,454 | |||||
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
A - Award | 2,222 | 2,222 | |||||
2020-07-28 |
|
4 | ANNX |
Annexon, Inc.
Series D Preferred Stock |
C - Conversion | -4,043,031 | 0 | -100.00 | ||||
2020-07-28 |
|
4 | ANNX |
Annexon, Inc.
Series D Preferred Stock |
C - Conversion | -4,043,032 | 0 | -100.00 | ||||
2020-07-28 |
|
4 | ANNX |
Annexon, Inc.
Common Stock |
P - Purchase | 350,000 | 808,914 | 76.27 | 17.00 | 5,950,000 | 13,751,538 | |
2020-07-28 |
|
4 | ANNX |
Annexon, Inc.
Common Stock |
P - Purchase | 350,000 | 808,914 | 76.27 | 17.00 | 5,950,000 | 13,751,538 | |
2020-07-28 |
|
4 | ANNX |
Annexon, Inc.
Common Stock |
C - Conversion | 458,914 | 458,914 | |||||
2020-07-28 |
|
4 | ANNX |
Annexon, Inc.
Common Stock |
C - Conversion | 458,914 | 458,914 | |||||
2020-07-22 |
|
4 | DFHT |
Deerfield Healthcare Technology Acquisitions Corp.
Class A common stock |
J - Other | 3,360,000 | 3,360,000 | 10.00 | 33,600,000 | 33,600,000 | ||
2020-07-14 |
|
4 | NKTX |
Nkarta, Inc.
Series B Preferred Stock |
C - Conversion | -2,626,767 | 0 | -100.00 | ||||
2020-07-14 |
|
4 | NKTX |
Nkarta, Inc.
Series B Preferred Stock |
C - Conversion | -2,626,767 | 0 | -100.00 | ||||
2020-07-14 |
|
4 | NKTX |
Nkarta, Inc.
Common Stock |
P - Purchase | 500,000 | 1,209,936 | 70.43 | 18.00 | 9,000,000 | 21,778,848 | |
2020-07-14 |
|
4 | NKTX |
Nkarta, Inc.
Common Stock |
P - Purchase | 500,000 | 1,209,936 | 70.43 | 18.00 | 9,000,000 | 21,778,848 | |
2020-07-14 |
|
4 | NKTX |
Nkarta, Inc.
Common Stock |
C - Conversion | 709,936 | 709,936 | |||||
2020-07-14 |
|
4 | NKTX |
Nkarta, Inc.
Common Stock |
C - Conversion | 709,936 | 709,936 | |||||
2020-06-16 |
|
4 | GBIO |
Generation Bio Co.
Series C Preferred Stock |
C - Conversion | -455,500 | 0 | -100.00 | ||||
2020-06-16 |
|
4 | GBIO |
Generation Bio Co.
Series B Preferred Stock |
C - Conversion | -1,093,410 | 0 | -100.00 | ||||
2020-06-16 |
|
4 | GBIO |
Generation Bio Co.
Common Stock |
P - Purchase | 225,000 | 1,186,215 | 23.41 | 19.00 | 4,275,000 | 22,538,085 | |
2020-06-16 |
|
4 | GBIO |
Generation Bio Co.
Common Stock |
C - Conversion | 257,883 | 961,215 | 36.67 | ||||
2020-06-16 |
|
4 | GBIO |
Generation Bio Co.
Common Stock |
C - Conversion | 703,332 | 703,332 | |||||
2020-06-08 | 3 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
12,182,500 | ||||||||
2020-06-08 | 3 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
12,182,500 | ||||||||
2020-06-08 | 3 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
12,182,500 | ||||||||
2020-06-08 | 3 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
12,182,500 | ||||||||
2020-06-08 | 3 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
12,182,500 | ||||||||
2020-06-08 | 3 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
12,182,500 | ||||||||
2020-06-08 | 3 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
12,182,500 | ||||||||
2020-06-08 | 3 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
12,182,500 | ||||||||
2020-06-08 | 3 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
12,182,500 | ||||||||
2020-06-08 | 3 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
12,182,500 | ||||||||
2020-03-20 | 3 | LUMO |
NEWLINK GENETICS CORP
Common Stock |
1,872,338 | ||||||||
2020-03-20 | 3 | LUMO |
NEWLINK GENETICS CORP
Common Stock |
1,872,338 | ||||||||
2020-03-20 | 3 | LUMO |
NEWLINK GENETICS CORP
Common Stock |
1,872,338 | ||||||||
2020-03-20 | 3 | LUMO |
NEWLINK GENETICS CORP
Common Stock |
1,872,338 | ||||||||
2020-03-20 | 3 | LUMO |
NEWLINK GENETICS CORP
Common Stock |
1,872,338 | ||||||||
2020-03-20 | 3 | LUMO |
NEWLINK GENETICS CORP
Common Stock |
1,872,338 | ||||||||
2020-03-17 |
|
4 | DFPH |
DFP HEALTHCARE ACQUISITIONS CORP.
Class A common stock |
J - Other | 2,500,000 | 2,500,000 | 10.00 | 25,000,000 | 25,000,000 | ||
2020-03-17 |
|
4 | DFPH |
DFP HEALTHCARE ACQUISITIONS CORP.
Class A common stock |
J - Other | 2,500,000 | 2,500,000 | 10.00 | 25,000,000 | 25,000,000 | ||
2020-02-18 |
|
4 | RVMD |
Revolution Medicines, Inc.
Series C Preferred Stock |
C - Conversion | -498,795 | 0 | -100.00 | ||||
2020-02-18 |
|
4 | RVMD |
Revolution Medicines, Inc.
Series C Preferred Stock |
C - Conversion | -997,589 | 0 | -100.00 | ||||
2020-02-18 |
|
4 | RVMD |
Revolution Medicines, Inc.
Common Stock |
P - Purchase | 300,000 | 798,795 | 60.14 | 17.00 | 5,100,000 | 13,579,515 | |
2020-02-18 |
|
4 | RVMD |
Revolution Medicines, Inc.
Common Stock |
P - Purchase | 300,000 | 798,795 | 60.14 | 17.00 | 5,100,000 | 13,579,515 | |
2020-02-18 |
|
4 | RVMD |
Revolution Medicines, Inc.
Common Stock |
C - Conversion | 498,795 | 498,795 | |||||
2020-02-18 |
|
4 | RVMD |
Revolution Medicines, Inc.
Common Stock |
C - Conversion | 997,589 | 997,589 | |||||
2020-02-10 |
|
4 | SDGR |
Schrodinger, Inc.
Series E Preferred Stock |
C - Conversion | -10,063,061 | 0 | -100.00 | ||||
2020-02-10 |
|
4 | SDGR |
Schrodinger, Inc.
Common Stock |
P - Purchase | 250,000 | 250,000 | 17.00 | 4,250,000 | 4,250,000 | ||
2020-02-10 |
|
4 | SDGR |
Schrodinger, Inc.
Common Stock |
C - Conversion | 1,346,167 | 1,346,167 | |||||
2020-02-03 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -1,142,361 | 0 | -100.00 | ||||
2020-02-03 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
P - Purchase | 400,000 | 778,790 | 105.60 | 19.00 | 7,600,000 | 14,797,010 | |
2020-02-03 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
C - Conversion | 378,790 | 378,790 | |||||
2020-01-31 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -509,970 | 0 | -100.00 | 15.45 | -7,879,036 | ||
2020-01-31 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -8,857 | 509,970 | -1.71 | 15.45 | -136,808 | 7,877,150 | |
2020-01-28 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -65,891 | 518,827 | -11.27 | 15.51 | -1,021,936 | 8,046,747 | |
2020-01-28 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -193,359 | 584,718 | -24.85 | 15.77 | -3,049,600 | 9,221,997 | |
2020-01-28 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -380,256 | 778,077 | -32.83 | 15.69 | -5,965,000 | 12,205,538 | |
2019-12-27 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -151,233 | 1,766,106 | -7.89 | 21.95 | -3,319,579 | 38,766,203 | |
2019-12-27 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -198,767 | 2,321,199 | -7.89 | 21.95 | -4,362,956 | 50,950,550 | |
2019-12-23 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -56,595 | 1,917,339 | -2.87 | 21.83 | -1,235,435 | 41,854,360 | |
2019-12-23 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -74,384 | 2,519,966 | -2.87 | 21.83 | -1,623,758 | 55,009,346 | |
2019-12-23 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -9,130 | 1,973,934 | -0.46 | 21.50 | -196,297 | 42,439,976 | |
2019-12-23 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -11,999 | 2,594,350 | -0.46 | 21.50 | -257,981 | 55,779,044 | |
2019-12-23 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -5,454 | 1,983,064 | -0.27 | 21.68 | -118,219 | 42,984,102 | |
2019-12-23 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -7,168 | 2,606,349 | -0.27 | 21.68 | -155,371 | 56,494,178 | |
2019-11-13 |
|
4 | AHCO |
AdaptHealth Corp.
Private Placement Warrants |
J - Other | -460,685 | 1,640,981 | -21.92 | ||||
2019-11-13 |
|
4 | AHCO |
AdaptHealth Corp.
Common Stock |
J - Other | -6,087 | 20,000 | -23.33 | ||||
2019-11-13 |
|
4 | AHCO |
AdaptHealth Corp.
Common Stock |
J - Other | -652,253 | 2,279,888 | -22.24 | ||||
2019-11-13 |
|
4 | AHCO |
AdaptHealth Corp.
Common Stock |
A - Award | 12,400,000 | 14,900,000 | 496.00 | 10.00 | 124,000,000 | 149,000,000 | |
2019-10-30 |
|
4 | CABA |
Cabaletta Bio, Inc.
Series B Preferred Stock |
C - Conversion | -696,379 | 0 | -100.00 | ||||
2019-10-30 |
|
4 | CABA |
Cabaletta Bio, Inc.
Series B Preferred Stock |
C - Conversion | -696,379 | 0 | -100.00 | ||||
2019-10-30 |
|
4 | CABA |
Cabaletta Bio, Inc.
Common Stock |
P - Purchase | 700,000 | 700,000 | 11.00 | 7,700,000 | 7,700,000 | ||
2019-10-30 |
|
4 | CABA |
Cabaletta Bio, Inc.
Common Stock |
C - Conversion | 464,253 | 464,253 | |||||
2019-10-30 |
|
4 | CABA |
Cabaletta Bio, Inc.
Common Stock |
C - Conversion | 464,253 | 464,253 | |||||
2019-10-07 |
|
4 | FREQ |
Frequency Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -3,184,948 | 0 | -100.00 | ||||
2019-10-07 |
|
4 | FREQ |
Frequency Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -3,184,948 | 0 | -100.00 | ||||
2019-10-07 |
|
4 | FREQ |
Frequency Therapeutics, Inc.
Common Stock |
P - Purchase | 285,714 | 285,714 | 14.00 | 3,999,996 | 3,999,996 | ||
2019-10-07 |
|
4 | FREQ |
Frequency Therapeutics, Inc.
Common Stock |
C - Conversion | 472,860 | 472,860 | |||||
2019-10-07 |
|
4 | FREQ |
Frequency Therapeutics, Inc.
Common Stock |
C - Conversion | 472,860 | 472,860 | |||||
2019-07-24 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Series A Preferred Stock |
C - Conversion | -12,467,650 | 0 | -100.00 | ||||
2019-07-24 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Series A Preferred Stock |
C - Conversion | -12,467,650 | 0 | -100.00 | ||||
2019-07-24 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 166,000 | 166,000 | 15.00 | 2,490,000 | 2,490,000 | ||
2019-07-24 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 166,000 | 166,000 | 15.00 | 2,490,000 | 2,490,000 | ||
2019-07-24 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1,558,456 | 1,558,456 | |||||
2019-07-24 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1,558,456 | 1,558,456 | |||||
2019-07-01 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -590,801 | 3,159,165 | -15.75 | 2.69 | -1,589,668 | 8,500,365 | |
2019-07-01 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -108,674 | 964,101 | -10.13 | 2.69 | -292,409 | 2,594,107 | |
2019-06-26 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -1,352 | 3,749,966 | -0.04 | 4.50 | -6,086 | 16,880,472 | |
2019-06-26 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -352 | 1,072,775 | -0.03 | 4.50 | -1,585 | 4,829,097 | |
2019-06-25 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -40,850 | 3,751,318 | -1.08 | 4.51 | -184,189 | 16,914,318 | |
2019-06-25 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -10,634 | 1,073,127 | -0.98 | 4.51 | -47,948 | 4,838,622 | |
2019-06-25 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -50,177 | 3,792,168 | -1.31 | 4.52 | -226,925 | 17,150,080 | |
2019-06-25 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -13,063 | 1,083,761 | -1.19 | 4.52 | -59,077 | 4,901,309 | |
2019-06-25 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -269,402 | 3,842,345 | -6.55 | 4.62 | -1,243,398 | 17,733,959 | |
2019-06-25 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -70,135 | 1,096,824 | -6.01 | 4.62 | -323,701 | 5,062,281 | |
2019-06-11 |
|
4 | FIXX |
Homology Medicines, Inc.
Stock Option (Right to Buy) |
A - Award | 15,580 | 15,580 | |||||
2019-05-13 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -71,869 | 1,166,959 | -5.80 | 6.05 | -434,750 | 7,059,168 | |
2019-05-13 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -108,696 | 4,111,747 | -2.58 | 6.05 | -657,524 | 24,872,780 | |
2019-05-13 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -172,800 | 1,238,828 | -12.24 | 6.16 | -1,064,016 | 7,628,083 | |
2019-05-13 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -261,345 | 4,220,443 | -5.83 | 6.16 | -1,609,232 | 25,987,378 | |
2019-04-15 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
P - Purchase | 533,333 | 1,158,333 | 85.33 | 22.50 | 11,999,992 | 26,062,492 | |
2019-03-11 |
|
4 | SWAV |
ShockWave Medical, Inc.
Series C Preferred Stock |
C - Conversion | -284,659 | 0 | -100.00 | ||||
2019-03-11 |
|
4 | SWAV |
ShockWave Medical, Inc.
Series C Preferred Stock |
C - Conversion | -284,659 | 0 | -100.00 | ||||
2019-03-11 |
|
4 | SWAV |
ShockWave Medical, Inc.
Series B Preferred Stock |
C - Conversion | -1,619,433 | 0 | -100.00 | ||||
2019-03-11 |
|
4 | SWAV |
ShockWave Medical, Inc.
Series B Preferred Stock |
C - Conversion | -1,619,433 | 0 | -100.00 | ||||
2019-03-11 |
|
4 | SWAV |
ShockWave Medical, Inc.
Common Stock |
P - Purchase | 10,000 | 10,000 | 17.00 | 170,000 | 170,000 | ||
2019-03-11 |
|
4 | SWAV |
ShockWave Medical, Inc.
Common Stock |
P - Purchase | 10,000 | 10,000 | 17.00 | 170,000 | 170,000 | ||
2019-03-11 |
|
4 | SWAV |
ShockWave Medical, Inc.
Common Stock |
P - Purchase | 10,000 | 10,000 | 17.00 | 170,000 | 170,000 | ||
2019-03-11 |
|
4 | SWAV |
ShockWave Medical, Inc.
Common Stock |
C - Conversion | 23,333 | 156,073 | 17.58 | ||||
2019-03-11 |
|
4 | SWAV |
ShockWave Medical, Inc.
Common Stock |
C - Conversion | 23,333 | 156,073 | 17.58 | ||||
2019-03-11 |
|
4 | SWAV |
ShockWave Medical, Inc.
Common Stock |
C - Conversion | 132,740 | 132,740 | |||||
2019-03-11 |
|
4 | SWAV |
ShockWave Medical, Inc.
Common Stock |
C - Conversion | 132,740 | 132,740 | |||||
2019-02-12 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -1,351 | 856,470 | -0.16 | 15.00 | -20,265 | 12,847,050 | |
2019-02-12 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -5,890 | 857,821 | -0.68 | 15.11 | -88,986 | 12,959,874 | |
2019-02-07 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -9,409 | 863,711 | -1.08 | 15.00 | -141,135 | 12,955,665 | |
2019-02-07 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -400 | 873,120 | -0.05 | 15.00 | -6,000 | 13,096,800 | |
2019-02-07 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -4,998 | 873,520 | -0.57 | 15.07 | -75,308 | 13,161,850 | |
2019-01-30 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -6,210 | 878,518 | -0.70 | 15.14 | -94,028 | 13,301,992 | |
2019-01-30 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -828 | 884,728 | -0.09 | 15.00 | -12,420 | 13,270,920 | |
2019-01-25 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -76,820 | 885,556 | -7.98 | 15.08 | -1,158,254 | 13,351,971 | |
2019-01-25 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -5,425 | 962,376 | -0.56 | 15.03 | -81,563 | 14,468,938 | |
2019-01-25 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -32,199 | 967,801 | -3.22 | 16.35 | -526,376 | 15,821,224 | |
2019-01-18 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Cash-Settled Total Return Swap |
J - Other | 1 | 1 | |||||
2019-01-18 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Cash-Settled Total Return Swap |
J - Other | 1 | 1 | |||||
2019-01-18 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Cash-Settled Total Return Swap |
J - Other | 1 | 1 | |||||
2019-01-02 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Cash-Settled Total Return Swap |
J - Other | 1 | 1 | |||||
2018-12-27 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Cash-Settled Total Return Swap |
J - Other | 1 | 1 | |||||
2018-12-27 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Cash-Settled Total Return Swap |
J - Other | 1 | 1 | |||||
2018-12-27 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Cash-Settled Total Return Swap |
J - Other | 1 | 1 | |||||
2018-12-21 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Cash-Settled Total Return Swap |
J - Other | 1 | 1 | |||||
2018-12-21 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Cash-Settled Total Return Swap |
J - Other | 1 | 1 | |||||
2018-12-21 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Cash-Settled Total Return Swap |
J - Other | 1 | 1 | |||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
10,375,204 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
7,305,044 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
10,375,204 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
7,305,044 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
10,375,204 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
7,305,044 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
10,375,204 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
7,305,044 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
10,375,204 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
7,305,044 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
10,375,204 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
7,305,044 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
10,375,204 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
7,305,044 | ||||||||
2018-10-01 |
|
4 | ARVN |
ARVINAS INC.
Series C Preferred Stock |
C - Conversion | -998,004 | 0 | -100.00 | ||||
2018-10-01 |
|
4 | ARVN |
ARVINAS INC.
Series C Preferred Stock |
C - Conversion | -998,004 | 0 | -100.00 | ||||
2018-10-01 |
|
4 | ARVN |
ARVINAS INC.
Series C Preferred Stock |
C - Conversion | -998,004 | 0 | -100.00 | ||||
2018-10-01 |
|
4 | ARVN |
ARVINAS INC.
Common Stock |
P - Purchase | 104,166 | 411,244 | 33.92 | 16.00 | 1,666,656 | 6,579,904 | |
2018-10-01 |
|
4 | ARVN |
ARVINAS INC.
Common Stock |
P - Purchase | 104,167 | 411,245 | 33.92 | 16.00 | 1,666,672 | 6,579,920 | |
2018-10-01 |
|
4 | ARVN |
ARVINAS INC.
Common Stock |
P - Purchase | 104,167 | 411,245 | 33.92 | 16.00 | 1,666,672 | 6,579,920 | |
2018-10-01 |
|
4 | ARVN |
ARVINAS INC.
Common Stock |
C - Conversion | 307,078 | 307,078 | |||||
2018-10-01 |
|
4 | ARVN |
ARVINAS INC.
Common Stock |
C - Conversion | 307,078 | 307,078 | |||||
2018-10-01 |
|
4 | ARVN |
ARVINAS INC.
Common Stock |
C - Conversion | 307,078 | 307,078 | |||||
2018-07-23 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Series F Preferred Stock |
C - Conversion | -7,000,000 | 0 | -100.00 | ||||
2018-07-23 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
P - Purchase | 200,000 | 835,843 | 31.45 | 15.00 | 3,000,000 | 12,537,645 | |
2018-07-23 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
C - Conversion | 635,843 | 635,843 | |||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
9,719,503 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
7,411,447 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
6,283,058 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
9,719,503 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
7,411,447 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
6,283,058 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
9,719,503 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
7,411,447 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
6,283,058 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
9,719,503 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
7,411,447 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
6,283,058 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
9,719,503 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
7,411,447 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
6,283,058 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
9,719,503 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
7,411,447 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
6,283,058 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
9,719,503 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
7,411,447 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
6,283,058 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
9,719,503 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
7,411,447 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
6,283,058 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
9,719,503 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
7,411,447 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
6,283,058 | ||||||||
2018-06-27 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -1,557,292 | 0 | -100.00 | ||||
2018-06-27 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -1,557,292 | 0 | -100.00 | ||||
2018-06-27 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
P - Purchase | 624,333 | 1,498,666 | 71.41 | 15.00 | 9,364,995 | 22,479,990 | |
2018-06-27 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
P - Purchase | 125,667 | 1,000,000 | 14.37 | 15.00 | 1,885,005 | 15,000,000 | |
2018-06-27 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 874,333 | 874,333 | |||||
2018-06-27 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 874,333 | 874,333 | |||||
2018-06-25 |
|
4 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
S - Sale | -114,034 | 952,265 | -10.69 | 5.99 | -683,315 | 5,706,162 | |
2018-06-12 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Stock Option (Right to Buy) |
A - Award | 12,700 | 12,700 | |||||
2018-05-31 |
|
4 | KNSA |
Kiniksa Pharmaceuticals, Ltd.
Series C Preferred Stock |
C - Conversion | -383,538 | 0 | -100.00 | ||||
2018-05-31 |
|
4 | KNSA |
Kiniksa Pharmaceuticals, Ltd.
Class A Common Stock |
P - Purchase | 235,019 | 843,352 | 38.63 | 19.24 | 4,520,943 | 16,223,141 | |
2018-05-31 |
|
4 | KNSA |
Kiniksa Pharmaceuticals, Ltd.
Class A Common Stock |
P - Purchase | 25,000 | 608,333 | 4.29 | 20.91 | 522,748 | 12,720,182 | |
2018-05-31 |
|
4 | KNSA |
Kiniksa Pharmaceuticals, Ltd.
Class A Common Stock |
P - Purchase | 250,000 | 583,333 | 75.00 | 19.81 | 4,953,150 | 11,557,343 | |
2018-05-31 |
|
4 | KNSA |
Kiniksa Pharmaceuticals, Ltd.
Class A Common Stock |
P - Purchase | 333,333 | 333,333 | 18.00 | 5,999,994 | 5,999,994 | ||
2018-05-31 |
|
4 | KNSA |
Kiniksa Pharmaceuticals, Ltd.
Class A Common Stock |
C - Conversion | 383,538 | 383,538 | |||||
2018-05-10 | 3 | MNK |
Mallinckrodt plc
Ordinary Shares, $0.20 par value |
17,242,766 | ||||||||
2018-05-10 | 3 | MNK |
Mallinckrodt plc
Ordinary Shares, $0.20 par value |
17,242,766 | ||||||||
2018-05-10 | 3 | MNK |
Mallinckrodt plc
Ordinary Shares, $0.20 par value |
17,242,766 | ||||||||
2018-05-10 | 3 | MNK |
Mallinckrodt plc
Ordinary Shares, $0.20 par value |
17,242,766 | ||||||||
2018-05-10 | 3 | MNK |
Mallinckrodt plc
Ordinary Shares, $0.20 par value |
17,242,766 | ||||||||
2018-05-10 | 3 | MNK |
Mallinckrodt plc
Ordinary Shares, $0.20 par value |
17,242,766 | ||||||||
2018-05-10 |
|
4 | MNK |
Mallinckrodt plc
Ordinary Shares, $0.20 par value |
S - Sale | -202,006 | 8,308,455 | -2.37 | 13.74 | -2,775,562 | 114,158,172 | |
2018-05-10 |
|
4 | MNK |
Mallinckrodt plc
Ordinary Shares, $0.20 par value |
S - Sale | -110,922 | 8,510,461 | -1.29 | 12.75 | -1,414,256 | 108,508,378 | |
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,854,839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,776,217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,920,342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,391,302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,854,839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,776,217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,920,342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,391,302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,854,839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,776,217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,920,342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,391,302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,854,839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,776,217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,920,342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,391,302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,854,839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,776,217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,920,342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,391,302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,854,839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,776,217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,920,342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,391,302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,854,839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,776,217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,920,342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,391,302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,854,839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,776,217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,920,342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,391,302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,854,839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,776,217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,920,342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4,391,302 | ||||||||
2018-04-04 |
|
4 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
J - Other | -3,913 | 26,087 | -13.04 | ||||
2018-04-04 |
|
4 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
J - Other | -921,848 | 6,045,652 | -13.23 | ||||
2018-04-04 |
|
4 | FIXX |
Homology Medicines, Inc.
Series B Preferred Stock |
C - Conversion | -6,944,444 | 0 | -100.00 | ||||
2018-04-04 |
|
4 | FIXX |
Homology Medicines, Inc.
Series B Preferred Stock |
C - Conversion | -6,944,445 | 0 | -100.00 | ||||
2018-04-04 |
|
4 | FIXX |
Homology Medicines, Inc.
Series A Preferred Stock |
C - Conversion | -3,521,126 | 0 | -100.00 | ||||
2018-04-04 |
|
4 | FIXX |
Homology Medicines, Inc.
Series A Preferred Stock |
C - Conversion | -3,521,126 | 0 | -100.00 | ||||
2018-04-04 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
P - Purchase | 625,000 | 625,000 | 16.00 | 10,000,000 | 10,000,000 | ||
2018-04-04 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
P - Purchase | 625,000 | 625,000 | 16.00 | 10,000,000 | 10,000,000 | ||
2018-04-04 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
C - Conversion | 1,319,483 | 1,988,517 | 197.22 | ||||
2018-04-04 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
C - Conversion | 1,319,484 | 1,988,518 | 197.22 | ||||
2018-04-04 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
C - Conversion | 669,034 | 669,034 | |||||
2018-04-04 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
C - Conversion | 669,034 | 669,034 | |||||
2018-03-29 |
|
4 | FIXX |
Homology Medicines, Inc.
Stock Option (Right to Buy) |
A - Award | 31,160 | 31,160 | |||||
2018-03-21 |
|
4/A | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -2,233 | 305,965 | -0.72 | 29.03 | -64,824 | 8,882,164 | |
2018-03-21 |
|
4/A | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -5,890 | 807,257 | -0.72 | 29.03 | -170,987 | 23,434,671 | |
2018-03-21 |
|
4/A | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -328 | 308,198 | -0.11 | 30.00 | -9,840 | 9,245,940 | |
2018-03-21 |
|
4/A | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -866 | 813,147 | -0.11 | 30.00 | -25,980 | 24,394,410 | |
2018-03-21 |
|
4/A | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -2,748 | 308,526 | -0.88 | 30.00 | -82,440 | 9,255,780 | |
2018-03-21 |
|
4/A | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -7,252 | 814,013 | -0.88 | 30.00 | -217,560 | 24,420,390 | |
2018-03-21 |
|
4/A | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -10,802 | 311,274 | -3.35 | 31.18 | -336,806 | 9,705,523 | |
2018-03-21 |
|
4/A | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -28,498 | 821,265 | -3.35 | 31.18 | -888,568 | 25,607,043 | |
2018-03-21 |
|
4/A | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -3,617 | 322,076 | -1.11 | 29.94 | -108,293 | 9,642,955 | |
2018-03-21 |
|
4/A | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -9,544 | 849,763 | -1.11 | 29.94 | -285,747 | 25,441,904 | |
2018-03-08 |
|
4 | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -8,123 | 1,113,222 | -0.72 | 29.03 | -235,811 | 32,316,835 | |
2018-03-08 |
|
4 | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -1,194 | 1,121,345 | -0.11 | 30.00 | -35,820 | 33,640,350 | |
2018-03-08 |
|
4 | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -10,000 | 1,122,539 | -0.88 | 30.00 | -300,000 | 33,676,170 | |
2018-03-08 |
|
4 | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -39,300 | 1,132,539 | -3.35 | 31.18 | -1,225,374 | 35,312,566 | |
2018-03-08 |
|
4 | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -13,161 | 1,171,839 | -1.11 | 29.94 | -394,040 | 35,084,860 | |
2018-02-23 |
|
4 | DFBH |
DFB Healthcare Acquisitions Corp.
Private Placement Warrants |
P - Purchase | 4,333,333 | 4,333,333 | 1.50 | 6,500,000 | 6,500,000 | ||
2018-02-23 |
|
4 | DFBH |
DFB Healthcare Acquisitions Corp.
Public Warrants |
P - Purchase | 833,333 | 833,333 | |||||
2018-02-23 |
|
4 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
P - Purchase | 2,500,000 | 2,500,000 | |||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
2,044,307 | ||||||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
1,510,693 | ||||||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
2,044,307 | ||||||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
1,510,693 | ||||||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
2,044,307 | ||||||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
1,510,693 | ||||||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
2,044,307 | ||||||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
1,510,693 | ||||||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
2,044,307 | ||||||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
1,510,693 | ||||||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
2,044,307 | ||||||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
1,510,693 | ||||||||
2018-02-15 | 3 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
13,965,000 | ||||||||
2018-02-15 | 3 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
7,027,500 | ||||||||
2018-02-15 | 3 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
13,965,000 | ||||||||
2018-02-15 | 3 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
7,027,500 | ||||||||
2018-02-15 | 3 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
13,965,000 | ||||||||
2018-02-15 | 3 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
7,027,500 | ||||||||
2018-02-15 | 3 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
13,965,000 | ||||||||
2018-02-15 | 3 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
7,027,500 | ||||||||
2018-02-15 | 3 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
13,965,000 | ||||||||
2018-02-15 | 3 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
7,027,500 | ||||||||
2017-12-04 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
S - Sale | -110,557 | 0 | -100.00 | 1.75 | -193,475 | ||
2017-12-04 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 110,557 | 197,424 | 127.27 | 1.75 | 193,475 | 345,492 | |
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Series A Preferred Stock |
C - Conversion | -2,668,518 | 0 | -100.00 | ||||
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Series A Preferred Stock |
C - Conversion | -2,668,518 | 0 | -100.00 | ||||
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 177,500 | 468,505 | 61.00 | 17.00 | 3,017,500 | 7,964,585 | |
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 177,500 | 468,505 | 61.00 | 17.00 | 3,017,500 | 7,964,585 | |
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 291,005 | 291,005 | |||||
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 291,005 | 291,005 | |||||
2017-08-04 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Stock Option (Right to Buy) |
A - Award | 13,333 | 13,333 | |||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
2,102,698 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,374,575 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,335,456 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,311,766 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
2,102,698 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,374,575 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,335,456 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,311,766 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
2,102,698 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,374,575 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,335,456 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,311,766 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
2,102,698 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,374,575 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,335,456 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,311,766 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
2,102,698 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,374,575 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,335,456 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,311,766 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
2,102,698 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,374,575 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,335,456 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,311,766 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
2,102,698 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,374,575 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,335,456 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,311,766 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
2,102,698 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,374,575 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,335,456 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,311,766 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
2,102,698 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,374,575 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,335,456 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,311,766 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
2,102,698 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,374,575 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,335,456 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,311,766 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
2,102,698 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,374,575 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,335,456 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1,311,766 | ||||||||
2017-06-14 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock |
S - Sale | -68,000 | 1,176,685 | -5.46 | 6.25 | -425,000 | 7,354,281 | |
2017-06-14 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock |
S - Sale | -32,447 | 1,244,685 | -2.54 | 6.59 | -213,826 | 8,202,474 | |
2017-06-14 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock |
S - Sale | -10,000 | 1,277,132 | -0.78 | 6.74 | -67,400 | 8,607,870 | |
2017-06-09 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock |
S - Sale | -17,245 | 1,287,132 | -1.32 | 6.99 | -120,543 | 8,997,053 | |
2017-06-09 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock |
S - Sale | -45,623 | 1,304,377 | -3.38 | 7.09 | -323,467 | 9,248,033 | |
2017-04-27 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -71,837 | 877,606 | -7.57 | 11.71 | -841,211 | 10,276,766 | |
2017-04-27 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -58,067 | 709,386 | -7.57 | 11.71 | -679,965 | 8,306,910 | |
2017-04-27 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -183,805 | 244,562 | -42.91 | 11.71 | -2,152,357 | 2,863,821 | |
2017-04-27 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -25,932 | 949,443 | -2.66 | 11.52 | -298,737 | 10,937,583 | |
2017-04-27 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -20,962 | 767,453 | -2.66 | 11.52 | -241,482 | 8,841,059 | |
2017-04-27 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -66,351 | 428,367 | -13.41 | 11.52 | -764,364 | 4,934,788 | |
2017-04-17 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -34,349 | 975,375 | -3.40 | 11.00 | -377,839 | 10,729,125 | |
2017-04-17 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -27,765 | 788,415 | -3.40 | 11.00 | -305,415 | 8,672,565 | |
2017-04-17 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -87,886 | 494,718 | -15.09 | 11.00 | -966,746 | 5,441,898 | |
2017-04-11 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -7,658 | 1,009,724 | -0.75 | 11.01 | -84,334 | 11,119,586 | |
2017-04-11 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -6,189 | 816,180 | -0.75 | 11.01 | -68,156 | 8,988,182 | |
2017-04-11 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -19,593 | 582,604 | -3.25 | 11.01 | -215,768 | 6,415,927 | |
2017-04-11 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -18,264 | 1,017,382 | -1.76 | 11.04 | -201,589 | 11,229,354 | |
2017-04-11 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -14,763 | 822,369 | -1.76 | 11.04 | -162,947 | 9,076,898 | |
2017-04-11 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -46,730 | 602,197 | -7.20 | 11.04 | -515,782 | 6,646,749 | |
2017-04-11 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -27,228 | 1,035,646 | -2.56 | 11.72 | -319,011 | 12,133,939 | |
2017-04-11 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -22,009 | 837,132 | -2.56 | 11.72 | -257,864 | 9,808,090 | |
2017-04-11 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -69,667 | 648,927 | -9.69 | 11.72 | -816,239 | 7,603,023 | |
2017-01-26 |
|
4 | CASM |
CAS MEDICAL SYSTEMS INC
Common Stock |
S - Sale | -517,450 | 2,358,636 | -17.99 | 1.46 | -752,941 | 3,432,051 | |
2017-01-26 |
|
4 | CASM |
CAS MEDICAL SYSTEMS INC
Common Stock |
S - Sale | -71,468 | 2,876,086 | -2.42 | 1.50 | -107,223 | 4,314,992 | |
2017-01-26 |
|
4 | CASM |
CAS MEDICAL SYSTEMS INC
Common Stock |
S - Sale | -47,320 | 2,947,554 | -1.58 | 1.50 | -71,065 | 4,426,637 | |
2017-01-23 |
|
4 | CASM |
CAS MEDICAL SYSTEMS INC
Common Stock |
S - Sale | -86,691 | 2,994,874 | -2.81 | 1.46 | -127,002 | 4,387,490 | |
2017-01-23 |
|
4 | CASM |
CAS MEDICAL SYSTEMS INC
Common Stock |
S - Sale | -46,522 | 3,081,565 | -1.49 | 1.53 | -71,267 | 4,720,649 | |
2017-01-23 |
|
4 | CASM |
CAS MEDICAL SYSTEMS INC
Common Stock |
S - Sale | -71,913 | 3,128,087 | -2.25 | 1.60 | -115,082 | 5,005,878 | |
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2,392,550 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2,482,450 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
3,425,000 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2,392,550 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2,482,450 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
3,425,000 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2,392,550 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2,482,450 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
3,425,000 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2,392,550 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2,482,450 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
3,425,000 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2,392,550 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2,482,450 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
3,425,000 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2,392,550 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2,482,450 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
3,425,000 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2,392,550 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2,482,450 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
3,425,000 | ||||||||
2016-12-14 |
|
4 | IVTY |
Invuity, Inc.
Common Stock |
S - Sale | -45,568 | 1,690,498 | -2.62 | 6.01 | -273,677 | 10,152,962 | |
2016-12-14 |
|
4 | IVTY |
Invuity, Inc.
Common Stock |
S - Sale | -71,173 | 1,736,066 | -3.94 | 6.13 | -436,148 | 10,638,612 | |
2016-12-14 |
|
4 | IVTY |
Invuity, Inc.
Common Stock |
S - Sale | -68,055 | 1,807,239 | -3.63 | 6.45 | -439,084 | 11,660,125 | |
2016-11-10 | 3 | IVTY |
Invuity, Inc.
Common Stock |
3,750,588 | ||||||||
2016-11-10 | 3 | IVTY |
Invuity, Inc.
Common Stock |
3,750,588 | ||||||||
2016-11-10 | 3 | IVTY |
Invuity, Inc.
Common Stock |
3,750,588 | ||||||||
2016-11-10 | 3 | IVTY |
Invuity, Inc.
Common Stock |
3,750,588 | ||||||||
2016-11-10 | 3 | IVTY |
Invuity, Inc.
Common Stock |
3,750,588 | ||||||||
2016-09-26 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -157,607 | 693,171 | -18.53 | 16.71 | -2,633,140 | 11,580,808 | |
2016-09-26 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -348,258 | 2,035,697 | -14.61 | 16.71 | -5,818,346 | 34,010,390 | |
2016-09-26 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -273,632 | 1,599,476 | -14.61 | 16.71 | -4,571,570 | 26,722,446 | |
2016-09-26 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -68,940 | 850,778 | -7.50 | 16.24 | -1,119,517 | 13,815,784 | |
2016-09-26 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -152,334 | 2,383,955 | -6.01 | 16.24 | -2,473,752 | 38,713,045 | |
2016-09-26 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -119,690 | 1,873,108 | -6.01 | 16.24 | -1,943,646 | 30,417,401 | |
2016-09-19 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -37,044 | 919,718 | -3.87 | 15.58 | -577,146 | 14,329,206 | |
2016-09-19 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -4,910 | 2,536,289 | -0.19 | 15.53 | -76,242 | 39,383,496 | |
2016-09-19 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -3,857 | 1,992,798 | -0.19 | 15.53 | -59,891 | 30,944,167 | |
2016-09-19 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -87,858 | 956,762 | -8.41 | 15.62 | -1,372,254 | 14,943,666 | |
2016-09-19 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -119,008 | 2,541,199 | -4.47 | 15.62 | -1,858,786 | 39,690,987 | |
2016-09-19 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -93,506 | 1,996,655 | -4.47 | 15.62 | -1,460,470 | 31,185,754 | |
2016-09-19 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -58,997 | 1,044,620 | -5.35 | 15.76 | -929,498 | 16,457,988 | |
2016-09-19 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -79,915 | 2,660,207 | -2.92 | 15.76 | -1,259,061 | 41,911,561 | |
2016-09-19 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -62,791 | 2,090,161 | -2.92 | 15.76 | -989,272 | 32,930,487 | |
2016-09-14 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 12,300 | 12,300 | |||||
2016-08-01 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
S - Sale | -901,430 | 1,151,802 | -43.90 | 3.31 | -2,985,356 | 3,814,538 | |
2016-08-01 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
S - Sale | -246,439 | 314,889 | -43.90 | 3.31 | -816,157 | 1,042,849 | |
2016-08-01 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
S - Sale | -193,630 | 247,413 | -43.90 | 3.31 | -641,264 | 819,382 | |
2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -99,830 | 0 | -100.00 | ||||
2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -99,830 | 0 | -100.00 | ||||
2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -267,998 | 0 | -100.00 | ||||
2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -535,996 | 0 | -100.00 | ||||
2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
P - Purchase | 146,596 | 514,424 | 39.85 | 15.00 | 2,198,940 | 7,716,360 | |
2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
P - Purchase | 253,404 | 889,230 | 39.85 | 15.00 | 3,801,060 | 13,338,450 | |
2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
C - Conversion | 99,830 | 367,828 | 37.25 | ||||
2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
C - Conversion | 99,830 | 367,828 | 37.25 | ||||
2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
C - Conversion | 267,998 | 267,998 | |||||
2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
C - Conversion | 535,996 | 535,996 | |||||
2016-07-21 |
|
4 | AXGN |
AxoGen, Inc.
Common Stock |
S - Sale | -102,136 | 3,000,000 | -3.29 | 6.70 | -684,311 | 20,100,000 | |
2016-07-18 |
|
4 | AXGN |
AxoGen, Inc.
Common Stock |
S - Sale | -41,425 | 3,102,136 | -1.32 | 6.87 | -284,590 | 21,311,674 | |
2016-07-18 |
|
4 | AXGN |
AxoGen, Inc.
Common Stock |
S - Sale | -31,788 | 3,143,561 | -1.00 | 7.32 | -232,688 | 23,010,867 | |
2016-07-18 |
|
4 | AXGN |
AxoGen, Inc.
Common Stock |
S - Sale | -206,090 | 3,175,349 | -6.09 | 7.70 | -1,586,893 | 24,450,187 | |
2016-07-06 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -508,566 | 0 | -100.00 | ||||
2016-07-06 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1,186,654 | 0 | -100.00 | ||||
2016-07-06 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 120,000 | 628,566 | 23.60 | 12.50 | 1,500,000 | 7,857,075 | |
2016-07-06 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 280,000 | 1,466,654 | 23.60 | 12.50 | 3,500,000 | 18,333,175 | |
2016-07-06 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 508,566 | 508,566 | |||||
2016-07-06 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1,186,654 | 1,186,654 | |||||
2016-06-22 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -26,400 | 718,594 | -3.54 | 14.30 | -377,552 | 10,276,757 | |
2016-06-22 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -178,454 | 744,994 | -19.32 | 14.20 | -2,533,511 | 10,576,680 | |
2016-06-16 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -43,300 | 923,448 | -4.48 | 13.88 | -601,169 | 12,820,967 | |
2016-06-08 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -28,080 | 966,748 | -2.82 | 13.84 | -388,633 | 13,379,986 | |
2016-06-08 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -7,154 | 994,828 | -0.71 | 13.89 | -99,380 | 13,819,653 | |
2016-06-08 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -28,502 | 1,001,982 | -2.77 | 14.00 | -399,037 | 14,028,049 | |
2016-06-02 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -42,668 | 1,030,484 | -3.98 | 13.87 | -591,741 | 14,291,267 | |
2016-06-02 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -5 | 1,073,152 | 0.00 | 13.80 | -69 | 14,809,498 | |
2016-06-02 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -56,835 | 1,073,157 | -5.03 | 13.84 | -786,625 | 14,853,029 | |
2016-05-27 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -72,649 | 1,129,992 | -6.04 | 14.00 | -1,016,926 | 15,817,402 | |
2016-05-27 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -93,965 | 1,202,641 | -7.25 | 14.16 | -1,330,808 | 17,032,764 | |
2016-05-27 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -45,967 | 1,296,606 | -3.42 | 14.25 | -655,172 | 18,480,655 | |
2016-02-23 |
|
4 | XNPT |
XENOPORT INC
Common Stock |
P - Purchase | 11,745 | 2,746,650 | 0.43 | 3.99 | 46,843 | 10,954,464 | |
2016-02-23 |
|
4 | XNPT |
XENOPORT INC
Common Stock |
P - Purchase | 9,228 | 2,158,084 | 0.43 | 3.99 | 36,804 | 8,607,086 | |
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Class D Preferred Stock |
C - Conversion | -117,998 | 0 | -100.00 | ||||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Class D Preferred Stock |
C - Conversion | -117,996 | 0 | -100.00 | ||||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Class C Preferred Stock |
C - Conversion | -1,182,941 | 0 | -100.00 | ||||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Class B-1 Preferred Stock |
C - Conversion | -67,448 | 0 | -100.00 | ||||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Common Stock |
P - Purchase | 112,000 | 112,000 | 20.00 | 2,240,000 | 2,240,000 | ||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Common Stock |
P - Purchase | 88,000 | 88,000 | 20.00 | 1,760,000 | 1,760,000 | ||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Common Stock |
P - Purchase | 163,702 | 413,611 | 65.50 | 20.00 | 3,274,040 | 8,272,220 | |
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Common Stock |
P - Purchase | 122,793 | 1,623,089 | 8.18 | 20.00 | 2,455,860 | 32,461,780 | |
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Common Stock |
C - Conversion | 117,998 | 249,909 | 89.45 | ||||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Common Stock |
C - Conversion | 117,996 | 1,500,296 | 8.54 | ||||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Common Stock |
C - Conversion | 1,182,941 | 1,382,300 | 593.37 | ||||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Common Stock |
C - Conversion | 67,448 | 199,359 | 51.13 | ||||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Class D Preferred Stock |
P - Purchase | 117,998 | 0 | -100.00 | 21.01 | 2,479,138 | ||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Class D Preferred Stock |
P - Purchase | 117,996 | 0 | -100.00 | 21.01 | 2,479,096 | ||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Common Stock |
P - Purchase | 131,911 | 131,911 | 18.48 | 2,437,715 | 2,437,715 | ||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Common Stock |
P - Purchase | 131,911 | 131,911 | 18.48 | 2,437,715 | 2,437,715 | ||
2016-02-17 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 13,872 | 2,053,232 | 0.68 | 6.25 | 86,653 | 12,825,719 | |
2016-02-17 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 28,377 | 561,328 | 5.32 | 6.25 | 177,260 | 3,506,391 | |
2016-02-17 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 22,296 | 441,043 | 5.32 | 6.25 | 139,274 | 2,755,019 | |
2016-02-16 |
|
4 | XNPT |
XENOPORT INC
Common Stock |
P - Purchase | 19,725 | 2,734,905 | 0.73 | 3.92 | 77,381 | 10,729,032 | |
2016-02-16 |
|
4 | XNPT |
XENOPORT INC
Common Stock |
P - Purchase | 15,499 | 2,148,856 | 0.73 | 3.92 | 60,803 | 8,429,962 | |
2016-02-16 |
|
4 | XNPT |
XENOPORT INC
Common Stock |
P - Purchase | 1,157,189 | 2,715,180 | 74.27 | 3.76 | 4,349,642 | 10,205,819 | |
2016-02-16 |
|
4 | XNPT |
XENOPORT INC
Common Stock |
P - Purchase | 909,221 | 2,133,357 | 74.27 | 3.76 | 3,417,580 | 8,018,862 | |
2016-02-16 |
|
4 | XNPT |
XENOPORT INC
Common Stock |
P - Purchase | 1,557,991 | 1,557,991 | 3.96 | 6,166,840 | 6,166,840 | ||
2016-02-16 |
|
4 | XNPT |
XENOPORT INC
Common Stock |
P - Purchase | 1,224,136 | 1,224,136 | 3.96 | 4,845,375 | 4,845,375 | ||
2016-02-12 |
|
4 | AVXS |
AveXis, Inc.
Stock Option (Right to Buy) |
A - Award | -8,385 | 8,385 | -50.00 | ||||
2016-02-12 |
|
4 | AVXS |
AveXis, Inc.
Stock Option (Right to Buy) |
A - Award | -18,111 | 18,111 | -50.00 | ||||
2016-02-11 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 504 | 2,039,360 | 0.02 | 6.19 | 3,119 | 12,620,375 | |
2016-02-11 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 1,030 | 532,951 | 0.19 | 6.19 | 6,374 | 3,298,114 | |
2016-02-11 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 810 | 418,747 | 0.19 | 6.19 | 5,013 | 2,591,374 | |
2016-02-11 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 32,501 | 2,038,856 | 1.62 | 6.23 | 202,556 | 12,706,762 | |
2016-02-11 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 66,486 | 531,921 | 14.28 | 6.23 | 414,361 | 3,315,091 | |
2016-02-11 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 52,239 | 417,937 | 14.28 | 6.23 | 325,569 | 2,604,709 | |
2016-02-11 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 24,484 | 2,006,355 | 1.24 | 5.73 | 140,271 | 11,494,608 | |
2016-02-11 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 50,086 | 465,435 | 12.06 | 5.73 | 286,948 | 2,666,524 | |
2016-02-11 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 39,353 | 365,698 | 12.06 | 5.73 | 225,457 | 2,095,120 | |
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
4,705,436 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3,049,910 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3,138,914 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
4,705,436 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3,049,910 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3,138,914 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
4,705,436 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3,049,910 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3,138,914 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
4,705,436 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3,049,910 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3,138,914 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
4,705,436 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3,049,910 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3,138,914 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
4,705,436 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3,049,910 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3,138,914 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
4,705,436 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3,049,910 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3,138,914 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395,733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395,733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395,733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395,733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395,733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395,733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395,733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395,733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395,733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395,733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395,733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395,733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395,733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395,733 | ||||||||
2016-02-08 |
|
4 | EDIT |
Editas Medicine, Inc.
Series B Preferred Stock |
C - Conversion | -854,700 | 0 | -100.00 | ||||
2016-02-08 |
|
4 | EDIT |
Editas Medicine, Inc.
Series B Preferred Stock |
C - Conversion | -854,700 | 0 | -100.00 | ||||
2016-02-08 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
P - Purchase | 100,000 | 954,700 | 11.70 | 16.00 | 1,600,000 | 15,275,200 | |
2016-02-08 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 854,700 | 854,700 | |||||
2016-02-08 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 854,700 | 854,700 | |||||
2016-01-22 |
|
4 | XNPT |
XENOPORT INC
Common Stock |
P - Purchase | 346,417 | 6,667,391 | 5.48 | 4.09 | 1,418,404 | 27,299,632 | |
2016-01-22 | 3 | XNPT |
XENOPORT INC
Common Stock |
12,641,948 | ||||||||
2016-01-22 | 3 | XNPT |
XENOPORT INC
Common Stock |
12,641,948 | ||||||||
2016-01-22 | 3 | XNPT |
XENOPORT INC
Common Stock |
12,641,948 | ||||||||
2016-01-22 | 3 | XNPT |
XENOPORT INC
Common Stock |
12,641,948 | ||||||||
2016-01-22 | 3 | XNPT |
XENOPORT INC
Common Stock |
12,641,948 | ||||||||
2015-12-18 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 3,239 | 1,103,617 | 0.29 | 8.97 | 29,042 | 9,895,582 | |
2015-12-18 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 4,441 | 2,740,122 | 0.16 | 8.97 | 39,820 | 24,569,304 | |
2015-12-18 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 3,490 | 2,152,952 | 0.16 | 8.97 | 31,293 | 19,304,444 | |
2015-12-18 |
|
4/A | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 93,634 | 1,100,378 | 9.30 | 8.61 | 806,086 | 9,473,044 | |
2015-12-18 |
|
4/A | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 128,374 | 2,735,681 | 4.92 | 8.61 | 1,105,159 | 23,551,204 | |
2015-12-18 |
|
4/A | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 100,864 | 2,149,462 | 4.92 | 8.61 | 868,328 | 18,504,503 | |
2015-12-18 |
|
4/A | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 29,902 | 1,006,744 | 3.06 | 8.59 | 256,864 | 8,648,132 | |
2015-12-18 |
|
4/A | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 40,997 | 2,607,307 | 1.60 | 8.59 | 352,172 | 22,397,289 | |
2015-12-18 |
|
4/A | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 32,211 | 2,048,598 | 1.60 | 8.59 | 276,699 | 17,597,867 | |
2015-12-17 |
|
4 | STRM |
STREAMLINE HEALTH SOLUTIONS INC.
Common Stock |
S - Sale | -226,000 | 1,875,500 | -10.75 | 1.20 | -271,968 | 2,256,977 | |
2015-12-17 |
|
4 | STRM |
STREAMLINE HEALTH SOLUTIONS INC.
Common Stock |
S - Sale | -116,464 | 2,101,500 | -5.25 | 1.23 | -142,831 | 2,577,280 | |
2015-12-17 |
|
4 | STRM |
STREAMLINE HEALTH SOLUTIONS INC.
Common Stock |
S - Sale | -54,795 | 2,217,964 | -2.41 | 1.34 | -73,486 | 2,974,512 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 93,634 | 1,100,378 | 9.30 | 8.61 | 806,086 | 9,473,044 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 128,374 | 2,726,895 | 4.94 | 8.61 | 1,105,159 | 23,475,566 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 100,864 | 2,158,248 | 4.90 | 8.61 | 868,328 | 18,580,141 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 29,902 | 1,006,744 | 3.06 | 8.59 | 256,864 | 8,648,132 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 32,211 | 2,598,521 | 1.26 | 8.59 | 276,699 | 22,321,815 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 40,997 | 2,057,384 | 2.03 | 8.59 | 352,172 | 17,673,340 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 11,506 | 976,842 | 1.19 | 9.00 | 103,554 | 8,791,578 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 15,775 | 2,566,310 | 0.62 | 9.00 | 141,975 | 23,096,790 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 12,395 | 2,016,387 | 0.62 | 9.00 | 111,555 | 18,147,483 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 213,358 | 965,336 | 28.37 | 8.21 | 1,751,883 | 7,926,374 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 292,515 | 2,550,535 | 12.95 | 8.21 | 2,401,841 | 20,942,443 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 229,833 | 2,003,992 | 12.95 | 8.21 | 1,887,159 | 16,454,778 | |
2015-12-08 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 27,530 | 728,718 | 3.93 | 3.04 | 83,774 | 2,217,489 | |
2015-12-08 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 27,529 | 4,760,408 | 0.58 | 3.04 | 83,771 | 14,485,922 | |
2015-12-08 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 68,294 | 701,188 | 10.79 | 3.00 | 204,848 | 2,103,213 | |
2015-12-08 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 68,294 | 701,188 | 10.79 | 3.00 | 204,848 | 2,103,213 | |
2015-12-08 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 40,301 | 632,894 | 6.80 | 3.01 | 121,169 | 1,902,859 | |
2015-12-08 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 40,301 | 632,894 | 6.80 | 3.01 | 121,169 | 1,902,859 | |
2015-12-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 53,487 | 592,593 | 9.92 | 3.00 | 160,589 | 1,779,201 | |
2015-12-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 53,486 | 4,624,284 | 1.17 | 3.00 | 160,586 | 13,883,950 | |
2015-12-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 55,257 | 539,106 | 11.42 | 2.98 | 164,876 | 1,608,584 | |
2015-12-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 55,257 | 539,106 | 11.42 | 2.98 | 164,876 | 1,608,584 | |
2015-12-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 12,882 | 483,849 | 2.74 | 3.05 | 39,273 | 1,475,110 | |
2015-12-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 12,883 | 4,515,541 | 0.29 | 3.05 | 39,276 | 13,766,530 | |
2015-11-10 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 36,625 | 470,967 | 8.43 | 2.98 | 109,241 | 1,404,753 | |
2015-11-10 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 36,625 | 470,967 | 8.43 | 2.98 | 109,241 | 1,404,753 | |
2015-11-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 8,271 | 434,342 | 1.94 | 3.00 | 24,813 | 1,303,026 | |
2015-11-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 8,271 | 434,342 | 1.94 | 3.00 | 24,813 | 1,303,026 | |
2015-10-29 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 13,165 | 426,071 | 3.19 | 2.99 | 39,363 | 1,273,952 | |
2015-10-29 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 13,165 | 426,071 | 3.19 | 2.99 | 39,363 | 1,273,952 | |
2015-10-29 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 16,506 | 412,906 | 4.16 | 3.00 | 49,518 | 1,238,718 | |
2015-10-29 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 16,506 | 412,906 | 4.16 | 3.00 | 49,518 | 1,238,718 | |
2015-10-26 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 17,117 | 396,400 | 4.51 | 3.00 | 51,361 | 1,189,438 | |
2015-10-26 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 17,116 | 4,428,091 | 0.39 | 3.00 | 51,358 | 13,286,930 | |
2015-10-26 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 12,090 | 379,283 | 3.29 | 3.00 | 36,270 | 1,137,849 | |
2015-10-26 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 12,091 | 4,410,975 | 0.27 | 3.00 | 36,273 | 13,232,925 | |
2015-10-26 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 975 | 367,193 | 0.27 | 3.00 | 2,925 | 1,101,579 | |
2015-10-26 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 975 | 367,193 | 0.27 | 3.00 | 2,925 | 1,101,579 | |
2015-10-21 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 80,342 | 366,218 | 28.10 | 3.00 | 241,042 | 1,098,727 | |
2015-10-21 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 80,342 | 366,218 | 28.10 | 3.00 | 241,042 | 1,098,727 | |
2015-10-21 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 50,065 | 285,876 | 21.23 | 3.00 | 150,060 | 856,856 | |
2015-10-21 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 50,065 | 285,876 | 21.23 | 3.00 | 150,060 | 856,856 | |
2015-10-21 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 64,613 | 235,811 | 37.74 | 2.92 | 188,825 | 689,134 | |
2015-10-21 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 64,613 | 235,811 | 37.74 | 2.92 | 188,825 | 689,134 | |
2015-10-14 |
|
4 | CTMX |
CytomX Therapeutics, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -160,512 | 0 | -100.00 | ||||
2015-10-14 |
|
4 | CTMX |
CytomX Therapeutics, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -160,512 | 0 | -100.00 | ||||
2015-10-14 |
|
4 | CTMX |
CytomX Therapeutics, Inc.
Common Stock |
P - Purchase | 114,488 | 275,000 | 71.33 | 12.00 | 1,373,856 | 3,300,000 | |
2015-10-14 |
|
4 | CTMX |
CytomX Therapeutics, Inc.
Common Stock |
P - Purchase | 510,512 | 671,024 | 318.05 | 12.00 | 6,126,144 | 8,052,288 | |
2015-10-14 |
|
4 | CTMX |
CytomX Therapeutics, Inc.
Common Stock |
C - Conversion | 160,512 | 160,512 | |||||
2015-10-14 |
|
4 | CTMX |
CytomX Therapeutics, Inc.
Common Stock |
C - Conversion | 160,512 | 160,512 | |||||
2015-10-09 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 71,540 | 171,198 | 71.79 | 2.53 | 180,710 | 432,446 | |
2015-10-09 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 71,540 | 171,198 | 71.79 | 2.53 | 180,710 | 432,446 | |
2015-10-09 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 19,817 | 99,658 | 24.82 | 2.50 | 49,542 | 249,145 | |
2015-10-09 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 19,816 | 4,131,349 | 0.48 | 2.50 | 49,540 | 10,328,372 | |
2015-10-09 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 69,536 | 79,841 | 674.78 | 2.30 | 159,724 | 183,395 | |
2015-10-09 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 69,536 | 79,841 | 674.78 | 2.30 | 159,724 | 183,395 | |
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8,483,188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,451,496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,622,413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,648,858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8,483,188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,451,496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,622,413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,648,858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8,483,188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,451,496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,622,413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,648,858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8,483,188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,451,496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,622,413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,648,858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8,483,188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,451,496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,622,413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,648,858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8,483,188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,451,496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,622,413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,648,858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8,483,188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,451,496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,622,413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,648,858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8,483,188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,451,496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,622,413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,648,858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8,483,188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,451,496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,622,413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,648,858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8,483,188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,451,496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,622,413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,648,858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8,483,188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,451,496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,622,413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,648,858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8,483,188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,451,496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,622,413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,648,858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8,483,188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,451,496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,622,413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,648,858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8,483,188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,451,496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,622,413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,648,858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8,483,188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,451,496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,622,413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,648,858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8,483,188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,451,496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,622,413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,648,858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8,483,188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,451,496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,622,413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,648,858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8,483,188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,451,496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,622,413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4,648,858 | ||||||||
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -83,930 | 5,348,776 | -1.54 | 1.69 | -142,018 | 9,050,664 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -106,820 | 6,807,533 | -1.54 | 1.69 | -180,750 | 11,519,027 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -59,248 | 3,294,817 | -1.77 | 1.69 | -100,254 | 5,575,160 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -34,450 | 5,432,706 | -0.63 | 1.83 | -63,044 | 9,941,852 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -43,845 | 6,914,353 | -0.63 | 1.83 | -80,236 | 12,653,266 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -11,081 | 3,354,065 | -0.33 | 1.82 | -20,176 | 6,107,082 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -15,696 | 5,467,156 | -0.29 | 1.82 | -28,579 | 9,954,598 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -19,976 | 6,958,198 | -0.29 | 1.82 | -36,372 | 12,669,487 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -23,700 | 3,365,146 | -0.70 | 1.81 | -42,897 | 6,090,914 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -33,572 | 5,482,852 | -0.61 | 1.81 | -60,765 | 9,923,962 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -42,728 | 6,978,174 | -0.61 | 1.81 | -77,338 | 12,630,495 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -368,676 | 5,516,424 | -6.26 | 1.81 | -669,036 | 10,010,655 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -469,224 | 7,020,902 | -6.26 | 1.81 | -851,501 | 12,740,831 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -226,857 | 5,885,100 | -3.71 | 1.80 | -408,774 | 10,604,362 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -288,726 | 7,490,126 | -3.71 | 1.80 | -520,255 | 13,496,458 | |
2015-09-22 |
|
4 | RGNX |
REGENXBIO Inc.
Series D Convertible Preferred Stock |
C - Conversion | -397,079 | 0 | -100.00 | ||||
2015-09-22 |
|
4 | RGNX |
REGENXBIO Inc.
Series C Convertible Preferred Stock |
C - Conversion | -771,963 | 0 | -100.00 | ||||
2015-09-22 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
P - Purchase | 49,000 | 49,000 | 22.00 | 1,078,000 | 1,078,000 | ||
2015-09-22 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
P - Purchase | 38,500 | 38,500 | 22.00 | 847,000 | 847,000 | ||
2015-09-22 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
P - Purchase | 87,500 | 1,256,542 | 7.48 | 22.00 | 1,925,000 | 27,643,924 | |
2015-09-22 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
C - Conversion | 397,079 | 1,169,042 | 51.44 | ||||
2015-09-22 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
C - Conversion | 771,963 | 771,963 | |||||
2015-09-22 |
|
4 | AXGN |
AxoGen, Inc.
Common Stock |
S - Sale | -345,000 | 3,381,439 | -9.26 | 5.50 | -1,897,983 | 18,602,649 | |
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Warrants to Purchase |
X - Other | -104,166 | 0 | -100.00 | ||||
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Warrants to Purchase |
X - Other | -104,166 | 0 | -100.00 | ||||
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -500,000 | 0 | -100.00 | ||||
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -500,000 | 0 | -100.00 | ||||
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Common Stock |
P - Purchase | 200,000 | 429,166 | 87.27 | 15.00 | 3,000,000 | 6,437,490 | |
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Common Stock |
P - Purchase | 200,000 | 429,166 | 87.27 | 15.00 | 3,000,000 | 6,437,490 | |
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Common Stock |
S - Sale | -83,333 | 229,166 | -26.67 | 15.00 | -1,249,995 | 3,437,490 | |
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Common Stock |
S - Sale | -83,333 | 229,166 | -26.67 | 15.00 | -1,249,995 | 3,437,490 | |
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Common Stock |
X - Other | 104,166 | 312,499 | 50.00 | 12.00 | 1,249,992 | 3,749,988 | |
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Common Stock |
X - Other | 104,166 | 312,499 | 50.00 | 12.00 | 1,249,992 | 3,749,988 | |
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Common Stock |
C - Conversion | 208,333 | 208,333 | |||||
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Common Stock |
C - Conversion | 208,333 | 208,333 | |||||
2015-07-21 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -31,261 | 6,111,957 | -0.51 | 2.14 | -66,995 | 13,098,535 | |
2015-07-21 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -39,787 | 7,778,852 | -0.51 | 2.14 | -85,268 | 16,670,858 | |
2015-07-21 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -4,048 | 6,143,218 | -0.07 | 2.13 | -8,622 | 13,085,054 | |
2015-07-21 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -5,152 | 7,818,639 | -0.07 | 2.13 | -10,974 | 16,653,701 | |
2015-07-21 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -3,245 | 6,147,266 | -0.05 | 2.12 | -6,879 | 13,032,204 | |
2015-07-21 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -4,131 | 7,823,791 | -0.05 | 2.12 | -8,758 | 16,586,437 | |
2015-07-21 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -8,096 | 6,150,511 | -0.13 | 2.11 | -17,083 | 12,977,578 | |
2015-07-21 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -10,304 | 7,827,922 | -0.13 | 2.11 | -21,741 | 16,516,915 | |
2015-07-21 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -55,338 | 6,158,607 | -0.89 | 2.20 | -121,921 | 13,568,643 | |
2015-07-21 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -70,431 | 7,838,226 | -0.89 | 2.20 | -155,174 | 17,269,180 | |
2015-07-13 | 3 | STRM |
STREAMLINE HEALTH SOLUTIONS INC.
Common Stock |
4,545,518 | ||||||||
2015-07-13 | 3 | STRM |
STREAMLINE HEALTH SOLUTIONS INC.
Common Stock |
4,545,518 | ||||||||
2015-07-13 | 3 | STRM |
STREAMLINE HEALTH SOLUTIONS INC.
Common Stock |
4,545,518 | ||||||||
2015-07-13 | 3 | STRM |
STREAMLINE HEALTH SOLUTIONS INC.
Common Stock |
4,545,518 | ||||||||
2015-07-13 | 3 | STRM |
STREAMLINE HEALTH SOLUTIONS INC.
Common Stock |
4,545,518 | ||||||||
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -19,598 | 6,213,945 | -0.31 | 2.07 | -40,501 | 12,841,739 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -24,943 | 7,908,657 | -0.31 | 2.07 | -51,547 | 16,344,031 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -43,956 | 6,233,543 | -0.70 | 2.06 | -90,330 | 12,809,931 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -55,944 | 7,933,600 | -0.70 | 2.06 | -114,965 | 16,303,548 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -43,956 | 6,277,499 | -0.70 | 2.04 | -89,890 | 12,837,485 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -55,944 | 7,989,544 | -0.70 | 2.04 | -114,405 | 16,338,617 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -44,000 | 6,321,455 | -0.69 | 2.06 | -90,420 | 12,990,590 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -56,000 | 8,045,488 | -0.69 | 2.06 | -115,080 | 16,533,478 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -44,000 | 6,365,455 | -0.69 | 2.04 | -89,980 | 13,017,355 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -56,000 | 8,101,488 | -0.69 | 2.04 | -114,520 | 16,567,543 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -41,650 | 6,409,455 | -0.65 | 2.10 | -87,369 | 13,445,114 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -53,009 | 8,157,488 | -0.65 | 2.10 | -111,197 | 17,111,963 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -24,108 | 6,451,105 | -0.37 | 2.09 | -50,395 | 13,485,390 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -30,684 | 8,210,497 | -0.37 | 2.09 | -64,142 | 17,163,223 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -2,244 | 6,475,213 | -0.03 | 2.08 | -4,679 | 13,500,819 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -2,856 | 8,241,181 | -0.03 | 2.08 | -5,955 | 17,182,862 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -3,476 | 6,477,457 | -0.05 | 2.08 | -7,247 | 13,505,498 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -4,424 | 8,244,037 | -0.05 | 2.08 | -9,224 | 17,188,817 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -15,928 | 6,480,933 | -0.25 | 2.08 | -33,130 | 13,480,341 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -20,272 | 8,248,461 | -0.25 | 2.08 | -42,166 | 17,156,799 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -67,577 | 6,496,861 | -1.03 | 2.12 | -143,371 | 13,783,740 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -86,007 | 8,268,733 | -1.03 | 2.12 | -182,472 | 17,542,944 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -16,689 | 6,564,438 | -0.25 | 2.12 | -35,362 | 13,909,388 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -21,240 | 8,354,740 | -0.25 | 2.12 | -45,005 | 17,702,859 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -4,664 | 6,581,127 | -0.07 | 2.11 | -9,841 | 13,886,178 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -5,936 | 8,375,980 | -0.07 | 2.11 | -12,525 | 17,673,318 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -14,624 | 6,585,791 | -0.22 | 2.10 | -30,735 | 13,841,357 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -18,612 | 8,381,916 | -0.22 | 2.10 | -39,117 | 17,616,273 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -136,170 | 6,600,415 | -2.02 | 2.08 | -283,887 | 13,760,545 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -173,307 | 8,400,528 | -2.02 | 2.08 | -361,310 | 17,513,421 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -69,914 | 3,388,846 | -2.02 | 2.08 | -145,757 | 7,065,066 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -82,300 | 6,736,585 | -1.21 | 2.08 | -170,962 | 13,993,908 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -104,745 | 8,573,835 | -1.21 | 2.08 | -217,587 | 17,810,427 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -42,255 | 3,458,760 | -1.21 | 2.08 | -87,776 | 7,184,882 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -21,784 | 6,818,885 | -0.32 | 2.18 | -47,406 | 14,839,258 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -27,726 | 8,678,580 | -0.32 | 2.18 | -60,337 | 18,886,326 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -11,185 | 3,501,015 | -0.32 | 2.18 | -24,341 | 7,618,909 | |
2015-07-01 |
|
4/A | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -79,586 | 6,840,669 | -1.15 | 2.24 | -178,098 | 15,308,049 | |
2015-07-01 |
|
4/A | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -101,291 | 8,706,306 | -1.15 | 2.24 | -226,669 | 19,482,972 | |
2015-07-01 |
|
4/A | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -33,627 | 3,512,200 | -0.95 | 2.24 | -75,251 | 7,859,601 | |
2015-07-01 |
|
4/A | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -51,755 | 6,920,255 | -0.74 | 2.25 | -116,490 | 15,576,110 | |
2015-07-01 |
|
4/A | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -65,870 | 8,807,597 | -0.74 | 2.25 | -148,260 | 19,824,139 | |
2015-07-01 |
|
4/A | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -22,405 | 3,545,827 | -0.63 | 2.25 | -50,429 | 7,980,947 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -79,586 | 6,853,826 | -1.15 | 2.24 | -178,098 | 15,337,492 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -101,291 | 8,723,052 | -1.15 | 2.24 | -226,669 | 19,520,446 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -33,627 | 3,518,297 | -0.95 | 2.24 | -75,251 | 7,873,245 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -38,598 | 6,933,412 | -0.55 | 2.25 | -86,876 | 15,605,724 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -49,124 | 8,824,343 | -0.55 | 2.25 | -110,568 | 19,861,831 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -16,308 | 3,551,924 | -0.46 | 2.25 | -36,706 | 7,994,671 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -37,919 | 6,972,010 | -0.54 | 2.25 | -85,318 | 15,687,022 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -48,260 | 8,873,467 | -0.54 | 2.25 | -108,585 | 19,965,301 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -16,021 | 3,568,232 | -0.45 | 2.25 | -36,047 | 8,028,522 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -27,085 | 7,009,929 | -0.38 | 2.25 | -60,941 | 15,772,340 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -34,471 | 8,921,727 | -0.38 | 2.25 | -77,560 | 20,073,886 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -11,444 | 3,584,253 | -0.32 | 2.25 | -25,749 | 8,064,569 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -27,164 | 7,037,014 | -0.38 | 2.34 | -63,466 | 16,441,280 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -34,572 | 8,956,198 | -0.38 | 2.34 | -80,774 | 20,925,261 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -11,477 | 3,595,697 | -0.32 | 2.34 | -26,815 | 8,400,986 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -29,214 | 7,064,178 | -0.41 | 2.30 | -67,192 | 16,247,609 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -37,181 | 8,990,770 | -0.41 | 2.30 | -85,516 | 20,678,771 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -12,344 | 3,607,174 | -0.34 | 2.30 | -28,391 | 8,296,500 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -41,245 | 7,093,392 | -0.58 | 2.29 | -94,418 | 16,238,193 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -52,494 | 9,027,951 | -0.58 | 2.29 | -120,169 | 20,666,785 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -17,427 | 3,619,518 | -0.48 | 2.29 | -39,894 | 8,285,801 | |
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 2 Preferred Stock |
C - Conversion | -936,839 | 0 | -100.00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 2 Preferred Stock |
C - Conversion | -817,541 | 0 | -100.00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 2 Preferred Stock |
C - Conversion | -85,962 | 0 | -100.00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 2 Preferred Stock |
C - Conversion | -54,385 | 0 | -100.00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 2 Preferred Stock |
C - Conversion | -385,962 | 0 | -100.00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 1 Preferred Stock |
C - Conversion | -1,243,423 | 0 | -100.00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 1 Preferred Stock |
C - Conversion | -1,085,085 | 0 | -100.00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 1 Preferred Stock |
C - Conversion | -1,401,003 | 0 | -100.00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 1 Preferred Stock |
C - Conversion | -869,667 | 0 | -100.00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 1 Preferred Stock |
C - Conversion | -2,013,613 | 0 | -100.00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
P - Purchase | 77,539 | 832,216 | 10.27 | 14.00 | 1,085,546 | 11,651,024 | |
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
P - Purchase | 67,666 | 726,242 | 10.27 | 14.00 | 947,324 | 10,167,388 | |
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
P - Purchase | 104,795 | 1,124,740 | 10.27 | 14.00 | 1,467,130 | 15,746,360 | |
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 324,278 | 754,677 | 75.34 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 282,984 | 658,576 | 75.34 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 29,755 | 647,152 | 4.82 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 18,825 | 402,062 | 4.91 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 133,597 | 1,019,945 | 15.07 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 430,399 | 430,399 | |||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 375,592 | 375,592 | |||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 484,944 | 617,397 | 366.13 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 301,027 | 383,237 | 366.17 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 696,993 | 886,348 | 368.09 | ||||
2015-06-23 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -67,475 | 7,134,637 | -0.94 | 2.35 | -158,499 | 16,759,262 | |
2015-06-23 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -85,877 | 9,080,445 | -0.94 | 2.35 | -201,725 | 21,329,965 | |
2015-06-23 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -28,510 | 3,636,945 | -0.78 | 2.35 | -66,970 | 8,543,184 | |
2015-06-23 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -65,479 | 7,202,112 | -0.90 | 2.41 | -157,569 | 17,331,162 | |
2015-06-23 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -83,338 | 9,166,322 | -0.90 | 2.41 | -200,545 | 22,057,837 | |
2015-06-23 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -27,666 | 3,665,455 | -0.75 | 2.41 | -66,575 | 8,820,551 | |
2015-06-23 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -52,518 | 7,267,591 | -0.72 | 2.41 | -126,337 | 17,482,917 | |
2015-06-23 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -66,842 | 9,249,660 | -0.72 | 2.41 | -160,795 | 22,250,982 | |
2015-06-23 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -22,190 | 3,693,121 | -0.60 | 2.41 | -53,380 | 8,884,172 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -1,447 | 7,320,109 | -0.02 | 2.48 | -3,589 | 18,153,870 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -1,842 | 9,316,502 | -0.02 | 2.48 | -4,568 | 23,104,925 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -611 | 3,715,311 | -0.02 | 2.48 | -1,515 | 9,213,971 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -76,728 | 7,321,556 | -1.04 | 2.48 | -189,948 | 18,125,244 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -97,654 | 9,318,344 | -1.04 | 2.48 | -241,752 | 23,068,492 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -32,419 | 3,715,922 | -0.86 | 2.48 | -80,256 | 9,199,137 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -19,889 | 7,398,284 | -0.27 | 2.41 | -47,839 | 17,795,093 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -25,313 | 9,415,998 | -0.27 | 2.41 | -60,885 | 22,648,300 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -8,403 | 3,748,341 | -0.22 | 2.41 | -20,212 | 9,015,885 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -43,506 | 7,418,173 | -0.58 | 2.40 | -104,506 | 17,819,193 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -55,372 | 9,441,311 | -0.58 | 2.40 | -133,009 | 22,678,973 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -18,382 | 3,756,744 | -0.49 | 2.40 | -44,155 | 9,024,075 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -35,915 | 7,461,679 | -0.48 | 2.40 | -86,322 | 17,934,145 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -45,710 | 9,496,683 | -0.48 | 2.40 | -109,864 | 22,825,278 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -15,175 | 3,775,126 | -0.40 | 2.40 | -36,473 | 9,073,515 | |
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486,233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536,475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593,380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486,233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536,475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593,380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486,233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536,475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593,380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486,233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536,475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593,380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486,233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536,475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593,380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486,233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536,475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593,380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486,233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536,475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593,380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486,233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536,475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593,380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486,233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536,475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593,380 | ||||||||
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -22,973 | 3,790,301 | -0.60 | 2.40 | -55,144 | 9,098,239 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -5,267 | 3,813,274 | -0.14 | 2.40 | -12,641 | 9,151,858 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -1,568 | 3,818,541 | -0.04 | 2.40 | -3,771 | 9,183,591 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -54,370 | 7,497,594 | -0.72 | 2.40 | -130,510 | 17,997,225 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -69,198 | 9,542,393 | -0.72 | 2.40 | -166,103 | 22,905,560 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -12,467 | 7,551,964 | -0.16 | 2.40 | -29,921 | 18,124,714 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -15,866 | 9,611,591 | -0.16 | 2.40 | -38,078 | 23,067,818 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -3,710 | 7,564,431 | -0.05 | 2.40 | -8,923 | 18,192,457 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -4,722 | 9,627,457 | -0.05 | 2.40 | -11,356 | 23,154,034 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -44,010 | 7,568,141 | -0.58 | 2.43 | -106,874 | 18,378,474 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -56,012 | 9,632,179 | -0.58 | 2.43 | -136,020 | 23,390,783 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -18,551 | 7,612,151 | -0.24 | 2.42 | -44,986 | 18,459,466 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -18,551 | 7,612,151 | -0.24 | 2.42 | -44,986 | 18,459,466 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -23,611 | 9,688,191 | -0.24 | 2.42 | -57,257 | 23,493,863 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -23,611 | 9,688,191 | -0.24 | 2.42 | -57,257 | 23,493,863 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -18,595 | 3,820,109 | -0.48 | 2.43 | -45,156 | 9,276,753 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -7,838 | 3,838,704 | -0.20 | 2.42 | -19,007 | 9,308,857 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -7,838 | 3,838,704 | -0.20 | 2.42 | -19,007 | 9,308,857 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -67,627 | 7,649,253 | -0.88 | 2.47 | -166,782 | 18,864,588 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -86,071 | 9,735,413 | -0.88 | 2.47 | -212,268 | 24,009,476 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -58,251 | 7,716,880 | -0.75 | 2.48 | -144,445 | 19,135,547 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -74,137 | 9,821,484 | -0.75 | 2.48 | -183,838 | 24,354,334 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -28,574 | 3,854,380 | -0.74 | 2.47 | -70,469 | 9,505,672 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -24,612 | 3,882,954 | -0.63 | 2.48 | -61,030 | 9,628,561 | |
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5,536,135 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
6,558,316 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
7,042,177 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5,536,135 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
6,558,316 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
7,042,177 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5,536,135 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
6,558,316 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
7,042,177 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5,536,135 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
6,558,316 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
7,042,177 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5,536,135 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
6,558,316 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
7,042,177 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5,536,135 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
6,558,316 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
7,042,177 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5,536,135 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
6,558,316 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
7,042,177 | ||||||||
2015-05-13 |
|
4 | LIFE |
aTYR PHARMA INC
Series E Preferred Stock |
C - Conversion | -2,234,137 | 0 | -100.00 | ||||
2015-05-13 |
|
4 | LIFE |
aTYR PHARMA INC
Series E Preferred Stock |
C - Conversion | -2,234,137 | 0 | -100.00 | ||||
2015-05-13 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
P - Purchase | 25,000 | 255,764 | 10.83 | 14.00 | 350,000 | 3,580,696 | |
2015-05-13 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
P - Purchase | 25,000 | 255,764 | 10.83 | 14.00 | 350,000 | 3,580,696 | |
2015-05-13 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
C - Conversion | 230,764 | 230,764 | |||||
2015-05-13 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
C - Conversion | 230,764 | 230,764 | |||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
29,353,449 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
31,473,939 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
25,485,884 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
29,353,449 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
31,473,939 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
25,485,884 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
29,353,449 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
31,473,939 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
25,485,884 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
29,353,449 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
31,473,939 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
25,485,884 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
29,353,449 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
31,473,939 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
25,485,884 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
29,353,449 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
31,473,939 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
25,485,884 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
29,353,449 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
31,473,939 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
25,485,884 | ||||||||
2015-05-07 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
U - Other | -973,379 | 0 | -100.00 | ||||
2015-05-07 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
U - Other | -849,426 | 0 | -100.00 | ||||
2015-05-07 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
U - Other | -1,182,943 | 0 | -100.00 | ||||
2015-05-07 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
U - Other | -953,286 | 0 | -100.00 | ||||
2015-05-07 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
U - Other | -490,069 | 0 | -100.00 | ||||
2015-04-09 |
|
4 | AXGN |
AxoGen, Inc.
Common Stock |
S - Sale | -144,385 | 3,726,439 | -3.73 | 3.25 | -469,251 | 12,110,927 | |
2015-03-25 |
|
4 | STDY |
SteadyMed Ltd.
Series E Preferred Stock |
C - Conversion | -34,205 | 0 | -100.00 | ||||
2015-03-25 |
|
4 | STDY |
SteadyMed Ltd.
Series E Preferred Stock |
C - Conversion | -34,205 | 0 | -100.00 | ||||
2015-03-25 |
|
4 | STDY |
SteadyMed Ltd.
Ordinary Shares |
P - Purchase | 558,440 | 823,529 | 210.66 | 8.50 | 4,746,740 | 6,999,996 | |
2015-03-25 |
|
4 | STDY |
SteadyMed Ltd.
Ordinary Shares |
P - Purchase | 179,115 | 444,204 | 67.57 | 8.50 | 1,522,478 | 3,775,734 | |
2015-03-25 |
|
4 | STDY |
SteadyMed Ltd.
Ordinary Shares |
C - Conversion | 265,089 | 265,089 | |||||
2015-03-25 |
|
4 | STDY |
SteadyMed Ltd.
Ordinary Shares |
C - Conversion | 265,089 | 265,089 | |||||
2015-03-09 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -742,029 | 1,062,874 | -41.11 | 9.52 | -7,064,116 | 10,118,560 | |
2015-03-09 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -600,544 | 859,141 | -41.14 | 9.52 | -5,717,179 | 8,179,022 | |
2015-02-19 |
|
4 | NVTA |
Invitae Corp
Series F Preferred Stock |
C - Conversion | -1,000,000 | 0 | -100.00 | ||||
2015-02-19 |
|
4 | NVTA |
Invitae Corp
Common Stock |
P - Purchase | 48,388 | 48,388 | 16.00 | 774,208 | 774,208 | ||
2015-02-19 |
|
4 | NVTA |
Invitae Corp
Common Stock |
P - Purchase | 39,112 | 39,112 | 16.00 | 625,792 | 625,792 | ||
2015-02-19 |
|
4 | NVTA |
Invitae Corp
Common Stock |
P - Purchase | 87,500 | 254,166 | 52.50 | 16.00 | 1,400,000 | 4,066,656 | |
2015-02-19 |
|
4 | NVTA |
Invitae Corp
Common Stock |
C - Conversion | 166,666 | 166,666 | |||||
2015-02-10 | 3 | AXGN |
AxoGen, Inc.
Common Stock |
7,741,648 | ||||||||
2015-02-10 | 3 | AXGN |
AxoGen, Inc.
Common Stock |
7,741,648 | ||||||||
2015-02-10 | 3 | AXGN |
AxoGen, Inc.
Common Stock |
7,741,648 | ||||||||
2015-02-10 | 3 | AXGN |
AxoGen, Inc.
Common Stock |
7,741,648 | ||||||||
2015-02-10 | 3 | AXGN |
AxoGen, Inc.
Common Stock |
7,741,648 | ||||||||
2015-02-02 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
U - Other | -3,469,974 | 0 | -100.00 | ||||
2015-02-02 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
U - Other | -2,797,408 | 0 | -100.00 | ||||
2015-01-28 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 192,240 | 973,379 | 24.61 | 56.50 | 10,861,560 | 54,995,914 | |
2015-01-28 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 167,760 | 849,426 | 24.61 | 56.50 | 9,478,440 | 47,992,569 | |
2015-01-28 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 566,825 | 1,182,943 | 92.00 | 56.50 | 32,025,612 | 66,836,280 | |
2015-01-28 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 458,175 | 953,286 | 92.54 | 56.50 | 25,886,888 | 53,860,659 | |
2015-01-28 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 115,000 | 490,069 | 30.66 | 56.50 | 6,497,500 | 27,688,898 | |
2015-01-16 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 420,280 | 1,804,903 | 30.35 | 20.45 | 8,594,726 | 36,910,266 | |
2015-01-16 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 339,720 | 1,459,685 | 30.33 | 20.45 | 6,947,274 | 29,850,558 | |
2015-01-16 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 132,720 | 1,384,623 | 10.60 | 19.84 | 2,632,501 | 27,463,997 | |
2015-01-16 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 107,280 | 1,119,965 | 10.59 | 19.84 | 2,127,899 | 22,214,506 | |
2015-01-05 |
|
4 | CASM |
CAS MEDICAL SYSTEMS INC
Common Stock |
S - Sale | -1,443,200 | 0 | -100.00 | 1.65 | -2,381,280 | ||
2015-01-05 |
|
4 | CASM |
CAS MEDICAL SYSTEMS INC
Common Stock |
P - Purchase | 1,443,200 | 3,200,000 | 82.15 | 1.65 | 2,381,280 | 5,280,000 | |
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4,588,361 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4,485,476 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5,252,554 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5,562,474 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4,588,361 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4,485,476 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5,252,554 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5,562,474 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4,588,361 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4,485,476 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5,252,554 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5,562,474 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4,588,361 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4,485,476 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5,252,554 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5,562,474 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4,588,361 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4,485,476 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5,252,554 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5,562,474 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4,588,361 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4,485,476 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5,252,554 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5,562,474 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4,588,361 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4,485,476 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5,252,554 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5,562,474 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4,588,361 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4,485,476 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5,252,554 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5,562,474 | ||||||||
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 20,580 | 1,674,781 | 1.24 | 14.48 | 297,998 | 24,250,829 | |
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 16,434 | 1,346,715 | 1.24 | 14.48 | 237,964 | 19,500,433 | |
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 13,900 | 1,654,201 | 0.85 | 14.30 | 198,770 | 23,655,074 | |
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 11,100 | 1,330,281 | 0.84 | 14.30 | 158,730 | 19,023,018 | |
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 11,120 | 1,640,301 | 0.68 | 14.33 | 159,350 | 23,505,513 | |
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 8,880 | 1,319,181 | 0.68 | 14.33 | 127,250 | 18,903,864 | |
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 13,900 | 1,629,181 | 0.86 | 14.50 | 201,550 | 23,623,124 | |
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 11,100 | 1,310,301 | 0.85 | 14.50 | 160,950 | 18,999,364 | |
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 16,680 | 1,615,281 | 1.04 | 14.48 | 241,526 | 23,389,269 | |
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 13,320 | 1,299,201 | 1.04 | 14.48 | 192,874 | 18,812,430 | |
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 13,900 | 1,598,601 | 0.88 | 14.23 | 197,797 | 22,748,092 | |
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 11,100 | 1,285,881 | 0.87 | 14.23 | 157,953 | 18,298,087 | |
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,324,172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,444,214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,565,221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,630,769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,730,242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,324,172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,444,214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,565,221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,630,769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,730,242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,324,172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,444,214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,565,221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,630,769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,730,242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,324,172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,444,214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,565,221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,630,769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,730,242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,324,172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,444,214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,565,221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,630,769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,730,242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,324,172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,444,214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,565,221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,630,769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,730,242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,324,172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,444,214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,565,221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,630,769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,730,242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,324,172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,444,214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,565,221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,630,769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,730,242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,324,172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,444,214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,565,221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,630,769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3,730,242 | ||||||||
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -55,035 | 800,794 | -6.43 | 11.50 | -632,902 | 9,209,131 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -48,027 | 698,822 | -6.43 | 11.50 | -552,310 | 8,036,453 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -18,903 | 275,046 | -6.43 | 11.50 | -217,384 | 3,163,029 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -3,785 | 855,829 | -0.44 | 11.54 | -43,679 | 9,876,267 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -3,303 | 746,849 | -0.44 | 11.54 | -38,117 | 8,618,637 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -14,199 | 293,949 | -4.61 | 11.55 | -163,998 | 3,395,111 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -41,339 | 859,614 | -4.59 | 11.55 | -477,465 | 9,928,542 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -36,074 | 750,152 | -4.59 | 11.55 | -416,655 | 8,664,256 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -1,300 | 308,148 | -0.42 | 11.54 | -15,002 | 3,556,028 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -45,124 | 900,953 | -4.77 | 11.00 | -496,364 | 9,910,483 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -39,377 | 786,226 | -4.77 | 11.00 | -433,147 | 8,648,486 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -15,499 | 309,448 | -4.77 | 11.00 | -170,489 | 3,403,928 | |
2014-11-10 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -30,100 | 0 | -100.00 | 9.33 | -280,833 | ||
2014-11-10 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -3,500 | 30,100 | -10.42 | 9.27 | -32,445 | 279,027 | |
2014-11-10 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -180,564 | 33,600 | -84.31 | 9.00 | -1,625,076 | 302,400 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Series D Purchase Right |
J - Other | -838,067 | 0 | -100.00 | ||||
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Series D Purchase Right |
J - Other | -1,049,472 | 0 | -100.00 | ||||
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Series D Purchase Right |
J - Other | -4,907,601 | 0 | -100.00 | ||||
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Series D Preferred Stock |
C - Conversion | -1,047,584 | 0 | -100.00 | ||||
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Series D Preferred Stock |
C - Conversion | -1,311,840 | 0 | -100.00 | ||||
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Series D Preferred Stock |
C - Conversion | -6,134,501 | 0 | -100.00 | ||||
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 45 | 170,371 | 0.03 | 10.00 | 450 | 1,703,710 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 55 | 208,345 | 0.03 | 10.00 | 550 | 2,083,450 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 272 | 170,326 | 0.16 | 10.00 | 2,720 | 1,703,260 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 328 | 208,290 | 0.16 | 10.00 | 3,280 | 2,082,900 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 12,819 | 170,054 | 8.15 | 10.00 | 128,190 | 1,700,540 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 15,417 | 207,962 | 8.01 | 10.00 | 154,170 | 2,079,620 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 5,801 | 157,235 | 3.83 | 10.00 | 58,010 | 1,572,350 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 6,976 | 192,545 | 3.76 | 10.00 | 69,760 | 1,925,450 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 81,949 | 151,434 | 117.94 | 10.00 | 819,490 | 1,514,340 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 98,556 | 185,569 | 113.27 | 10.00 | 985,560 | 1,855,690 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 469,495 | 876,391 | 115.38 | 10.00 | 4,694,950 | 8,763,910 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
C - Conversion | 69,485 | 69,485 | |||||
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
C - Conversion | 87,013 | 87,013 | |||||
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
C - Conversion | 406,896 | 406,896 | |||||
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -51,449 | 214,164 | -19.37 | 10.01 | -515,004 | 2,143,782 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -14,464 | 946,077 | -1.51 | 11.02 | -159,393 | 10,425,769 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -12,622 | 825,603 | -1.51 | 11.02 | -139,094 | 9,098,145 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -4,061 | 265,613 | -1.51 | 11.02 | -44,752 | 2,927,055 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -4,968 | 324,947 | -1.51 | 11.02 | -54,747 | 3,580,916 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -246 | 960,541 | -0.03 | 12.00 | -2,952 | 11,528,413 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -215 | 838,225 | -0.03 | 12.00 | -2,580 | 10,060,376 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -69 | 269,674 | -0.03 | 12.00 | -828 | 3,236,627 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -84 | 330 | -20.29 | 12.00 | -1,008 | 3,960 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -11,855 | 960,787 | -1.22 | 12.14 | -143,860 | 11,659,150 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -10,345 | 838,440 | -1.22 | 12.14 | -125,537 | 10,174,469 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -3,328 | 269,743 | -1.22 | 12.14 | -40,385 | 3,273,331 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -4,072 | 329,999 | -1.22 | 12.14 | -49,414 | 4,004,538 | |
2014-10-01 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
1.50% Convertible Senior Notes due 2018 |
S - Sale | 0 | 1,974,921.00 | |||||
2014-10-01 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
1.50% Convertible Senior Notes due 2018 |
S - Sale | 0 | 1,599,314.00 | |||||
2014-10-01 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
1.50% Convertible Senior Notes due 2018 |
S - Sale | 2,528,763.00 | ||||||
2014-10-01 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
1.50% Convertible Senior Notes due 2018 |
S - Sale | 2,048,365.00 | ||||||
2014-09-25 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
1.50% Convertible Senior Notes due 2018 |
S - Sale | 603,102.00 | ||||||
2014-09-25 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
1.50% Convertible Senior Notes due 2018 |
S - Sale | 743,108.00 | ||||||
2014-09-25 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
1.50% Convertible Senior Notes due 2018 |
S - Sale | 5,960,963.00 | ||||||
2014-09-25 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
1.50% Convertible Senior Notes due 2018 |
S - Sale | 7,357,516.00 | ||||||
2014-09-25 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
1.50% Convertible Senior Notes due 2018 |
S - Sale | 4,852,505.67 | ||||||
2014-09-25 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
1.50% Convertible Senior Notes due 2018 |
S - Sale | 5,988,054.33 | ||||||
2014-08-11 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 1,731 | 1,251,903 | 0.14 | 21.05 | 36,438 | 26,352,558 | |
2014-08-11 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 1,400 | 1,012,685 | 0.14 | 21.05 | 29,470 | 21,317,019 | |
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Series B Preferred Stock |
C - Conversion | -222,839 | 0 | -100.00 | ||||
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Series B Preferred Stock |
C - Conversion | -279,051 | 0 | -100.00 | ||||
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
P - Purchase | 77,256 | 296,125 | 35.30 | 13.05 | 1,008,191 | 3,864,431 | |
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
P - Purchase | 218,869 | 218,869 | 13.00 | 2,845,297 | 2,845,297 | ||
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
P - Purchase | 62,400 | 239,300 | 35.27 | 13.05 | 814,320 | 3,122,865 | |
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
P - Purchase | 176,900 | 176,900 | 13.00 | 2,299,700 | 2,299,700 | ||
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
P - Purchase | 246,631 | 469,470 | 110.68 | 13.00 | 3,206,203 | 6,103,110 | |
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
P - Purchase | 307,600 | 586,651 | 110.23 | 13.00 | 3,998,800 | 7,626,463 | |
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
C - Conversion | 222,839 | 222,839 | |||||
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
C - Conversion | 279,051 | 279,051 | |||||
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Series B Preferred Stock |
C - Conversion | -531,208 | 0 | -100.00 | ||||
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Series B Preferred Stock |
C - Conversion | -147,410 | 0 | -100.00 | ||||
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Series B Preferred Stock |
C - Conversion | -184,594 | 0 | -100.00 | ||||
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 31,650 | 627,267 | 5.31 | 24.57 | 777,640 | 15,411,950 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 49,981 | 595,617 | 9.16 | 26.35 | 1,316,999 | 15,694,508 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 27,600 | 545,636 | 5.33 | 26.14 | 721,464 | 14,262,925 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 12,400 | 518,036 | 2.45 | 27.54 | 341,496 | 14,266,711 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 219,864 | 505,636 | 76.94 | 26.42 | 5,808,807 | 13,358,903 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 18,700 | 285,772 | 7.00 | 25.79 | 482,273 | 7,370,060 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 9,800 | 267,072 | 3.81 | 25.52 | 250,096 | 6,815,677 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 201,972 | 257,272 | 365.23 | 25.41 | 5,132,109 | 6,537,282 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 55,300 | 55,300 | 17.00 | 940,100 | 940,100 | ||
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 25,600 | 507,200 | 5.32 | 24.57 | 628,992 | 12,461,904 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 40,400 | 481,600 | 9.16 | 26.35 | 1,064,540 | 12,690,160 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 22,400 | 441,200 | 5.35 | 26.14 | 585,536 | 11,532,968 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 10,100 | 418,800 | 2.47 | 27.54 | 278,154 | 11,533,752 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 177,700 | 408,700 | 76.93 | 26.42 | 4,694,834 | 10,797,854 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 15,100 | 231,000 | 6.99 | 25.79 | 389,429 | 5,957,490 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 7,900 | 215,900 | 3.80 | 25.52 | 201,608 | 5,509,768 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 163,300 | 208,000 | 365.32 | 25.41 | 4,149,453 | 5,285,280 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 44,700 | 44,700 | 17.00 | 759,900 | 759,900 | ||
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 123,077 | 654,285 | 23.17 | 17.00 | 2,092,309 | 11,122,845 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 34,223 | 181,633 | 23.22 | 17.00 | 581,791 | 3,087,761 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 42,700 | 227,294 | 23.13 | 17.00 | 725,900 | 3,863,998 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
C - Conversion | 531,208 | 531,208 | |||||
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
C - Conversion | 147,410 | 147,410 | |||||
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
C - Conversion | 184,594 | 184,594 | |||||
2014-08-05 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 2,085 | 1,250,172 | 0.17 | 20.99 | 43,764 | 26,241,110 | |
2014-08-05 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 1,685 | 1,011,285 | 0.17 | 20.99 | 35,368 | 21,226,872 | |
2014-08-05 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 78,853 | 1,248,087 | 6.74 | 20.75 | 1,636,200 | 25,897,805 | |
2014-08-05 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 7,122 | 1,169,234 | 0.61 | 20.40 | 145,289 | 23,852,374 | |
2014-08-05 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 63,738 | 1,009,600 | 6.74 | 20.75 | 1,322,564 | 20,949,200 | |
2014-08-05 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 5,757 | 945,862 | 0.61 | 20.40 | 117,443 | 19,295,585 | |
2014-08-05 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 13,272 | 1,162,112 | 1.16 | 19.40 | 257,477 | 22,544,973 | |
2014-08-05 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 80,904 | 1,148,840 | 7.58 | 19.04 | 1,540,412 | 21,873,914 | |
2014-08-05 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 10,728 | 940,105 | 1.15 | 19.40 | 208,123 | 18,238,037 | |
2014-08-05 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 65,396 | 929,377 | 7.57 | 19.04 | 1,245,140 | 17,695,338 | |
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2,795,898 | ||||||||
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2,999,853 | ||||||||
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2,795,898 | ||||||||
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2,999,853 | ||||||||
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2,795,898 | ||||||||
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2,999,853 | ||||||||
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2,795,898 | ||||||||
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2,999,853 | ||||||||
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2,795,898 | ||||||||
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2,999,853 | ||||||||
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2,795,898 | ||||||||
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2,999,853 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9,064,790 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9,737,356 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9,064,790 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9,737,356 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9,064,790 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9,737,356 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9,064,790 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9,737,356 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9,064,790 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9,737,356 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9,064,790 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9,737,356 | ||||||||
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series E Preferred Stock |
C - Conversion | -253,384 | 0 | -100.00 | ||||
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series E Preferred Stock |
C - Conversion | -221,118 | 0 | -100.00 | ||||
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series E Preferred Stock |
C - Conversion | -71,333 | 0 | -100.00 | ||||
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series E Preferred Stock |
C - Conversion | -86,834 | 0 | -100.00 | ||||
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 75,480 | 261,143 | 40.65 | 11.97 | 903,126 | 3,124,602 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 94,520 | 324,524 | 41.09 | 11.97 | 1,130,941 | 3,882,962 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 19,980 | 185,663 | 12.06 | 12.29 | 245,468 | 2,281,000 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 25,020 | 230,004 | 12.21 | 12.29 | 307,388 | 2,825,760 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 340,425 | 593,809 | 134.35 | 12.00 | 4,085,100 | 7,125,708 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 297,075 | 518,193 | 134.35 | 12.00 | 3,564,900 | 6,218,316 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 94,350 | 165,683 | 132.27 | 12.00 | 1,132,200 | 1,988,196 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 118,150 | 204,984 | 136.06 | 12.00 | 1,417,800 | 2,459,808 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 253,384 | 253,384 | |||||
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 221,118 | 221,118 | |||||
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 71,333 | 71,333 | |||||
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 86,834 | 86,834 | |||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Series E Preferred Stock |
C - Conversion | -2,323,086 | 0 | -100.00 | ||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Series E Preferred Stock |
C - Conversion | -2,027,262 | 0 | -100.00 | ||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Series E Preferred Stock |
C - Conversion | -654,002 | 0 | -100.00 | ||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Series E Preferred Stock |
C - Conversion | -796,114 | 0 | -100.00 | ||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 280,350 | 796,591 | 54.31 | 12.00 | 3,364,200 | 9,559,092 | |
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 244,650 | 695,152 | 54.31 | 12.00 | 2,935,800 | 8,341,824 | |
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 78,400 | 223,733 | 53.95 | 12.00 | 940,800 | 2,684,796 | |
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 96,600 | 273,514 | 54.60 | 12.00 | 1,159,200 | 3,282,168 | |
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 516,241 | 796,591 | 184.14 | ||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 450,502 | 695,152 | 184.14 | ||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 145,333 | 223,733 | 185.37 | ||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 176,914 | 273,514 | 183.14 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series C Preferred Stock |
C - Conversion | -572,142 | 0 | -100.00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series C Preferred Stock |
C - Conversion | -499,285 | 0 | -100.00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series C Preferred Stock |
C - Conversion | -161,071 | 0 | -100.00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series C Preferred Stock |
C - Conversion | -196,071 | 0 | -100.00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
P - Purchase | 400,500 | 972,642 | 70.00 | 15.00 | 6,007,500 | 14,589,630 | |
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
P - Purchase | 349,500 | 848,785 | 70.00 | 15.00 | 5,242,500 | 12,731,775 | |
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
P - Purchase | 112,000 | 273,071 | 69.53 | 15.00 | 1,680,000 | 4,096,065 | |
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
P - Purchase | 138,000 | 334,071 | 70.38 | 15.00 | 2,070,000 | 5,011,065 | |
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 572,142 | 972,642 | 142.86 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 499,285 | 848,785 | 142.86 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 161,071 | 273,071 | 143.81 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 196,071 | 334,071 | 142.08 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock Warrants (right to buy) |
S - Sale | -187,149 | 0 | -100.00 | 0.38 | -70,817 | ||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock Warrants (right to buy) |
S - Sale | -116,172 | 0 | -100.00 | 0.38 | -43,959 | ||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock Warrants (right to buy) |
S - Sale | -39,249 | 0 | -100.00 | 0.38 | -14,852 | ||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock Warrants (right to buy) |
S - Sale | -21,414 | 0 | -100.00 | 0.38 | -8,103 | ||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
C - Conversion | -9,258 | 0 | -100.00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
C - Conversion | -5,748 | 0 | -100.00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
C - Conversion | -1,938 | 0 | -100.00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
C - Conversion | -1,056 | 0 | -100.00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -19,620 | 0 | -100.00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -12,179 | 0 | -100.00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -4,114 | 0 | -100.00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -2,243 | 0 | -100.00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -21,213 | 0 | -100.00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -13,168 | 0 | -100.00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -4,448 | 0 | -100.00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -2,426 | 0 | -100.00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -14,005,557 | 0 | -100.00 | 0.06 | -785,712 | ||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 2,830,978 | 14,005,557 | 25.33 | 0.35 | 990,842 | 4,901,945 | |
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 7,323,275 | 11,174,579 | 190.15 | 0.30 | 2,196,982 | 3,352,374 | |
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 3,714,455 | 3,851,304 | 2,714.27 | 0.74 | 2,733,839 | 2,834,560 | |
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -8,694,231 | 0 | -100.00 | 0.06 | -487,746 | ||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 1,757,664 | 8,694,231 | 25.34 | 0.35 | 615,182 | 3,042,981 | |
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 4,545,880 | 6,936,567 | 190.15 | 0.30 | 1,363,764 | 2,080,970 | |
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 2,305,753 | 2,390,687 | 2,714.76 | 0.74 | 1,697,034 | 1,759,546 | |
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -2,974,566 | 0 | -100.00 | 0.06 | -166,873 | ||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 592,613 | 2,974,566 | 24.88 | 0.35 | 207,415 | 1,041,098 | |
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 1,535,573 | 2,381,953 | 181.43 | 0.30 | 460,672 | 714,586 | |
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 778,856 | 846,380 | 1,153.45 | 0.74 | 573,238 | 622,936 | |
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -1,619,176 | 0 | -100.00 | 0.06 | -90,836 | ||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 322,911 | 1,619,176 | 24.91 | 0.35 | 113,019 | 566,712 | |
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 837,215 | 1,296,265 | 182.38 | 0.30 | 251,164 | 388,880 | |
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 424,798 | 459,050 | 1,240.21 | 0.74 | 312,651 | 337,861 | |
2013-07-17 | 3 | CASM |
CAS MEDICAL SYSTEMS INC
Common Stock |
1,756,800 | ||||||||
2013-07-17 | 3 | CASM |
CAS MEDICAL SYSTEMS INC
Common Stock |
1,443,200 | ||||||||
2013-01-15 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 3,086 | 9,258 | 50.00 | 100.00 | 308,600 | 925,800 | |
2013-01-15 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 1,916 | 5,748 | 50.00 | 100.00 | 191,600 | 574,800 | |
2013-01-15 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 646 | 1,938 | 50.00 | 100.00 | 64,600 | 193,800 | |
2013-01-15 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 352 | 1,056 | 50.00 | 100.00 | 35,200 | 105,600 | |
2012-12-20 | 3 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
514,128 | ||||||||
2012-12-20 | 3 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
603,464 | ||||||||
2012-12-14 | 3 | NXTM |
NxStage Medical, Inc.
Common Stock |
2,422,121 | ||||||||
2012-12-14 | 3 | NXTM |
NxStage Medical, Inc.
Common Stock |
3,223,783 | ||||||||
2012-12-14 | 3 | NXTM |
NxStage Medical, Inc.
Common Stock |
70,820 | ||||||||
2012-12-14 | 3 | NXTM |
NxStage Medical, Inc.
Common Stock |
83,137 | ||||||||
2012-11-16 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 1,543 | 6,172 | 33.33 | 100.00 | 154,300 | 617,200 | |
2012-11-16 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 958 | 3,832 | 33.33 | 100.00 | 95,800 | 383,200 | |
2012-11-16 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 323 | 1,292 | 33.33 | 100.00 | 32,300 | 129,200 | |
2012-11-16 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 176 | 704 | 33.33 | 100.00 | 17,600 | 70,400 | |
2012-10-10 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -3,510 | 0 | -100.00 | ||||
2012-10-10 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -2,179 | 0 | -100.00 | ||||
2012-10-10 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -736 | 0 | -100.00 | ||||
2012-10-10 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -401 | 0 | -100.00 | ||||
2012-10-10 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 3,510 | 19,620 | 21.79 | 100.00 | 351,000 | 1,962,000 | |
2012-10-10 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 2,179 | 12,179 | 21.79 | 100.00 | 217,900 | 1,217,900 | |
2012-10-10 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 736 | 4,114 | 21.79 | 100.00 | 73,600 | 411,400 | |
2012-10-10 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 401 | 2,243 | 21.77 | 100.00 | 40,100 | 224,300 | |
2012-08-21 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 3,086 | 4,629 | 200.00 | 100.00 | 308,600 | 462,900 | |
2012-08-21 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 1,916 | 2,874 | 200.00 | 100.00 | 191,600 | 287,400 | |
2012-08-21 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 646 | 969 | 200.00 | 100.00 | 64,600 | 96,900 | |
2012-08-21 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 352 | 528 | 200.00 | 100.00 | 35,200 | 52,800 | |
2012-07-09 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -228,392 | 136,849 | -62.53 | 1.22 | -278,638 | 166,956 | |
2012-07-09 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -141,750 | 84,934 | -62.53 | 1.22 | -172,935 | 103,619 | |
2012-07-09 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -112,693 | 67,524 | -62.53 | 1.22 | -137,485 | 82,379 | |
2012-07-09 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -57,165 | 34,252 | -62.53 | 1.22 | -69,741 | 41,787 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 1,543 | 1,543 | 100.00 | 154,300 | 154,300 | ||
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 958 | 958 | 100.00 | 95,800 | 95,800 | ||
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 323 | 323 | 100.00 | 32,300 | 32,300 | ||
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 176 | 176 | 100.00 | 17,600 | 17,600 | ||
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -283,180 | 299,811 | -48.57 | 1.33 | -376,629 | 398,749 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -175,782 | 186,037 | -48.58 | 1.33 | -233,790 | 247,429 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -59,388 | 252,561 | -19.04 | 1.33 | -78,986 | 335,906 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -32,402 | 125,150 | -20.57 | 1.33 | -43,095 | 166,450 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -85,623 | 582,991 | -12.81 | 1.20 | -102,748 | 699,589 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -53,150 | 361,819 | -12.81 | 1.20 | -63,780 | 434,183 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -17,957 | 311,949 | -5.44 | 1.20 | -21,548 | 374,339 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -9,797 | 157,552 | -5.85 | 1.20 | -11,756 | 189,062 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -3,472 | 1 | -99.97 | ||||
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -2,155 | 1 | -99.95 | ||||
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -728 | 1 | -99.86 | ||||
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -397 | 1 | -99.75 | ||||
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 3,472 | 16,110 | 27.47 | 100.00 | 347,200 | 1,611,000 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 2,155 | 10,000 | 27.47 | 100.00 | 215,500 | 1,000,000 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 728 | 3,378 | 27.47 | 100.00 | 72,800 | 337,800 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 397 | 1,842 | 27.47 | 100.00 | 39,700 | 184,200 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -82,321 | 668,614 | -10.96 | 1.14 | -93,846 | 762,220 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -51,091 | 414,969 | -10.96 | 1.14 | -58,244 | 473,065 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -40,619 | 329,906 | -10.96 | 1.14 | -46,306 | 376,093 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -20,604 | 167,349 | -10.96 | 1.14 | -23,489 | 190,778 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -92,964 | 750,935 | -11.02 | 1.07 | -99,471 | 803,500 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -57,697 | 466,060 | -11.02 | 1.07 | -61,736 | 498,684 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -45,871 | 370,525 | -11.02 | 1.07 | -49,082 | 396,462 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -23,268 | 187,953 | -11.02 | 1.07 | -24,897 | 201,110 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -49,170 | 843,899 | -5.51 | 1.00 | -49,170 | 843,899 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -30,517 | 523,757 | -5.51 | 1.00 | -30,517 | 523,757 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -24,262 | 416,396 | -5.51 | 1.00 | -24,262 | 416,396 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -12,307 | 211,221 | -5.51 | 1.00 | -12,307 | 211,221 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -26,357 | 893,069 | -2.87 | 0.98 | -25,830 | 875,208 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -16,358 | 554,274 | -2.87 | 0.98 | -16,031 | 543,189 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -13,005 | 440,658 | -2.87 | 0.98 | -12,745 | 431,845 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -6,597 | 223,528 | -2.87 | 0.98 | -6,465 | 219,057 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -27,500 | 919,426 | -2.90 | 0.98 | -26,950 | 901,037 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -70,184 | 946,926 | -6.90 | 0.99 | -69,482 | 937,457 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -17,123 | 570,632 | -2.91 | 0.98 | -16,781 | 559,219 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -43,600 | 587,755 | -6.91 | 0.99 | -43,164 | 581,877 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -11,900 | 453,663 | -2.56 | 0.98 | -11,662 | 444,590 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -30,400 | 465,563 | -6.13 | 0.99 | -30,096 | 460,907 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -8,577 | 230,125 | -3.59 | 0.98 | -8,405 | 225,522 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -21,816 | 238,702 | -8.37 | 0.99 | -21,598 | 236,315 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -3,472 | 1 | -99.97 | ||||
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -2,155 | 1 | -99.95 | ||||
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -728 | 1 | -99.86 | ||||
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -397 | 1 | -99.75 | ||||
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 3,472 | 12,638 | 37.88 | 100.00 | 347,200 | 1,263,800 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 2,155 | 7,845 | 37.87 | 100.00 | 215,500 | 784,500 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 728 | 2,650 | 37.88 | 100.00 | 72,800 | 265,000 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 397 | 1,445 | 37.88 | 100.00 | 39,700 | 144,500 | |
2012-03-23 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -48,600 | 1,017,110 | -4.56 | 1.05 | -51,030 | 1,067,966 | |
2012-03-23 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -30,226 | 631,355 | -4.57 | 1.05 | -31,737 | 662,923 | |
2012-03-23 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -21,074 | 495,963 | -4.08 | 1.05 | -22,128 | 520,761 | |
2012-03-23 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -15,100 | 260,518 | -5.48 | 1.05 | -15,855 | 273,544 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -15,025 | 1,065,710 | -1.39 | 1.01 | -15,175 | 1,076,367 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -9,326 | 661,581 | -1.39 | 1.01 | -9,419 | 668,197 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -7,290 | 517,037 | -1.39 | 1.01 | -7,363 | 522,207 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -3,885 | 275,618 | -1.39 | 1.01 | -3,924 | 278,374 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -7,824 | 1,080,735 | -0.72 | 1.04 | -8,137 | 1,123,964 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -4,857 | 670,907 | -0.72 | 1.04 | -5,051 | 697,743 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -3,796 | 524,327 | -0.72 | 1.04 | -3,948 | 545,300 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -2,023 | 279,503 | -0.72 | 1.04 | -2,104 | 290,683 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -52,094 | 1,088,559 | -4.57 | 1.11 | -57,824 | 1,208,300 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -32,339 | 675,764 | -4.57 | 1.11 | -35,896 | 750,098 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -25,275 | 528,123 | -4.57 | 1.11 | -28,055 | 586,217 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -13,472 | 281,526 | -4.57 | 1.11 | -14,954 | 312,494 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -64,706 | 1,140,653 | -5.37 | 1.20 | -77,647 | 1,368,784 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -40,167 | 708,103 | -5.37 | 1.20 | -48,200 | 849,724 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -31,393 | 553,398 | -5.37 | 1.20 | -37,672 | 664,078 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -16,734 | 294,998 | -5.37 | 1.20 | -20,081 | 353,998 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -23,261 | 1,205,359 | -1.89 | 1.04 | -24,191 | 1,253,573 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -14,439 | 748,270 | -1.89 | 1.04 | -15,017 | 778,201 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -11,285 | 584,791 | -1.89 | 1.04 | -11,736 | 608,183 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -6,015 | 311,732 | -1.89 | 1.04 | -6,256 | 324,201 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -8,881 | 1,228,620 | -0.72 | 0.99 | -8,792 | 1,216,334 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -5,513 | 762,709 | -0.72 | 0.99 | -5,458 | 755,082 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -4,310 | 596,076 | -0.72 | 0.99 | -4,267 | 590,115 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -2,296 | 317,747 | -0.72 | 0.99 | -2,273 | 314,570 | |
2012-02-08 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -10,600 | 1,237,501 | -0.85 | 0.98 | -10,388 | 1,212,751 | |
2012-02-08 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -6,536 | 768,222 | -0.84 | 0.98 | -6,405 | 752,858 | |
2012-02-08 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -4,564 | 600,386 | -0.75 | 0.98 | -4,473 | 588,378 | |
2012-02-08 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -3,300 | 320,043 | -1.02 | 0.98 | -3,234 | 313,642 | |
2011-06-07 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
P - Purchase | 301,424 | 3,204,167 | 10.38 | 8.00 | 2,411,392 | 25,633,336 | |
2011-06-07 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
P - Purchase | 229,252 | 2,279,997 | 11.18 | 8.00 | 1,834,016 | 18,239,976 | |
2011-06-07 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
P - Purchase | 72,800 | 762,700 | 10.55 | 8.00 | 582,400 | 6,101,600 | |
2011-06-07 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
P - Purchase | 46,524 | 470,425 | 10.98 | 8.00 | 372,192 | 3,763,400 | |
2010-12-14 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -11,557 | 781,833 | -1.46 | 0.51 | -5,894 | 398,735 | |
2010-12-14 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -6,443 | 435,887 | -1.46 | 0.51 | -3,286 | 222,302 | |
2010-12-14 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -8,925 | 793,390 | -1.11 | 0.50 | -4,462 | 396,695 | |
2010-12-14 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -4,975 | 442,330 | -1.11 | 0.50 | -2,488 | 221,165 | |
2010-12-14 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -192,615 | 802,315 | -19.36 | 0.51 | -98,234 | 409,181 | |
2010-12-14 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -107,385 | 447,305 | -19.36 | 0.51 | -54,766 | 228,126 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -20,995 | 994,930 | -2.07 | 0.58 | -12,177 | 577,059 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -11,705 | 554,690 | -2.07 | 0.58 | -6,789 | 321,720 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -88,905 | 1,015,925 | -8.05 | 0.56 | -49,787 | 568,918 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -49,565 | 566,395 | -8.05 | 0.56 | -27,756 | 317,181 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -290,692 | 1,104,830 | -20.83 | 0.60 | -174,415 | 662,898 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -162,064 | 615,960 | -20.83 | 0.60 | -97,238 | 369,576 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -1,011 | 1,395,522 | -0.07 | 0.55 | -556 | 767,537 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -563 | 778,024 | -0.07 | 0.55 | -310 | 427,913 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -128,003 | 1,396,533 | -8.40 | 0.56 | -71,682 | 782,058 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -71,362 | 778,587 | -8.40 | 0.56 | -39,963 | 436,009 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -10,209 | 1,524,536 | -0.67 | 0.53 | -5,411 | 808,004 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -5,691 | 849,949 | -0.67 | 0.53 | -3,016 | 450,473 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -193 | 1,534,745 | -0.01 | 0.59 | -114 | 905,500 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -107 | 855,640 | -0.01 | 0.59 | -63 | 504,828 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -34,724 | 1,534,938 | -2.21 | 0.58 | -20,140 | 890,264 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -19,358 | 855,747 | -2.21 | 0.58 | -11,228 | 496,333 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -4,816 | 1,569,662 | -0.31 | 0.58 | -2,793 | 910,404 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -2,684 | 875,105 | -0.31 | 0.58 | -1,557 | 507,561 | |
2010-11-05 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
S - Sale | -3,690 | 2,902,743 | -0.13 | 7.55 | -27,860 | 21,915,710 | |
2010-11-05 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
S - Sale | -2,605 | 2,050,745 | -0.13 | 7.55 | -19,668 | 15,483,125 | |
2010-11-05 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
S - Sale | -900 | 689,900 | -0.13 | 7.55 | -6,795 | 5,208,745 | |
2010-11-05 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
S - Sale | -516 | 423,901 | -0.12 | 7.55 | -3,896 | 3,200,453 | |
2010-11-05 | 3 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
2,053,350 | ||||||||
2010-11-05 | 3 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
2,906,433 | ||||||||
2010-11-05 | 3 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
424,417 | ||||||||
2010-11-05 | 3 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
690,800 | ||||||||
2010-11-05 | 3 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
25,000 | ||||||||
2010-10-28 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -63,563 | 1,574,478 | -3.88 | 0.59 | -37,502 | 928,942 | |
2010-10-28 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -35,437 | 877,789 | -3.88 | 0.59 | -20,908 | 517,896 | |
2010-09-28 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -129 | 1,638,041 | -0.01 | 0.58 | -75 | 950,064 | |
2010-09-28 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -71 | 913,226 | -0.01 | 0.58 | -41 | 529,671 | |
2010-09-28 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -12,842 | 1,638,170 | -0.78 | 0.58 | -7,448 | 950,139 | |
2010-09-28 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -7,158 | 913,297 | -0.78 | 0.58 | -4,152 | 529,712 | |
2010-09-23 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -1,443 | 1,651,012 | -0.09 | 0.59 | -851 | 974,097 | |
2010-09-23 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -804 | 920,455 | -0.09 | 0.59 | -474 | 543,068 | |
2010-09-23 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -2 | 1,652,455 | 0.00 | 0.58 | -1 | 958,424 | |
2010-09-23 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -28,553 | 1,652,457 | -1.70 | 0.59 | -16,846 | 974,950 | |
2010-09-23 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -15,917 | 921,259 | -1.70 | 0.59 | -9,391 | 543,543 | |
2010-09-23 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -4,559 | 1,681,010 | -0.27 | 0.58 | -2,644 | 974,986 | |
2010-09-23 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -2,541 | 937,176 | -0.27 | 0.58 | -1,474 | 543,562 | |
2010-09-17 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -192,616 | 1,685,569 | -10.26 | 0.58 | -111,717 | 977,630 | |
2010-09-17 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -107,384 | 939,717 | -10.26 | 0.58 | -62,283 | 545,036 | |
2010-09-17 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -256,821 | 1,878,185 | -12.03 | 0.59 | -151,524 | 1,108,129 | |
2010-09-17 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -143,179 | 1,047,101 | -12.03 | 0.59 | -84,476 | 617,790 | |
2010-09-17 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -40,129 | 2,135,006 | -1.84 | 0.60 | -24,077 | 1,281,004 | |
2010-09-17 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -22,371 | 1,190,280 | -1.84 | 0.60 | -13,423 | 714,168 | |
2010-08-23 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -3,780 | 2,175,135 | -0.17 | 0.89 | -3,364 | 1,935,870 | |
2010-08-23 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -2,107 | 1,212,651 | -0.17 | 0.89 | -1,875 | 1,079,259 | |
2010-08-23 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -642,053 | 2,178,915 | -22.76 | 0.78 | -500,801 | 1,699,554 | |
2010-08-23 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -357,947 | 1,214,758 | -22.76 | 0.78 | -279,199 | 947,511 | |
2009-09-11 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock Warrants (right to buy) |
P - Purchase | 1,544,750 | 1,544,750 | 0.12 | 193,094 | 193,094 | ||
2009-09-11 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock Warrants (right to buy) |
P - Purchase | 876,489 | 876,489 | 0.12 | 109,561 | 109,561 | ||
2009-09-11 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
P - Purchase | 1,626,053 | 2,820,968 | 136.08 | 2.00 | 3,252,106 | 5,641,936 | |
2009-09-11 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
P - Purchase | 922,620 | 1,572,705 | 141.92 | 2.00 | 1,845,240 | 3,145,410 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -133,445 | 2,941,480 | -4.34 | 13.16 | -1,756,136 | 38,709,877 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -66,555 | 1,928,520 | -3.34 | 13.16 | -875,864 | 25,379,323 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -33,361 | 3,074,925 | -1.07 | 13.06 | -435,695 | 40,158,520 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -16,639 | 1,995,075 | -0.83 | 13.06 | -217,305 | 26,055,680 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -200,168 | 3,108,286 | -6.05 | 13.01 | -2,604,186 | 40,438,801 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -99,832 | 2,011,714 | -4.73 | 13.01 | -1,298,814 | 26,172,399 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -64,720 | 3,308,454 | -1.92 | 13.49 | -873,073 | 44,631,044 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -32,280 | 2,111,546 | -1.51 | 13.49 | -435,457 | 28,484,756 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -41,980 | 3,373,174 | -1.23 | 13.06 | -548,259 | 44,053,652 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -20,937 | 2,143,826 | -0.97 | 13.06 | -273,437 | 27,998,368 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -22,782 | 3,415,154 | -0.66 | 13.32 | -303,456 | 45,489,851 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -11,361 | 2,164,763 | -0.52 | 13.32 | -151,329 | 28,834,643 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -145,704 | 3,437,936 | -4.07 | 12.98 | -1,891,238 | 44,624,409 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -25,000 | 3,583,640 | -0.69 | 12.96 | -324,000 | 46,443,974 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -111,189 | 3,608,640 | -2.99 | 12.98 | -1,443,233 | 46,840,147 | |
2009-08-20 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -10,921 | 3,719,829 | -0.29 | 12.98 | -141,755 | 48,283,380 | |
2009-08-20 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -70,000 | 3,730,750 | -1.84 | 12.96 | -907,200 | 48,350,520 | |
2009-07-29 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | 14,852 | 3,800,750 | 0.39 | 12.55 | 186,393 | 47,699,412 | |
2009-07-29 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -9,901 | 2,176,124 | -0.45 | 12.55 | -124,258 | 27,310,356 | |
2009-07-29 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | 113,182 | 3,815,602 | 3.06 | 12.98 | 1,469,102 | 49,526,514 | |
2009-07-29 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -75,448 | 2,186,025 | -3.34 | 12.98 | -979,315 | 28,374,604 | |
2009-07-29 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -86,540 | 3,928,784 | -2.16 | 13.11 | -1,134,539 | 51,506,358 | |
2009-07-29 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -57,689 | 2,261,473 | -2.49 | 13.11 | -756,303 | 29,647,911 | |
2009-01-02 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 21,588 | 3,957,249 | 0.55 | 8.54 | 184,362 | 33,794,906 | |
2009-01-02 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 12,462 | 2,285,637 | 0.55 | 8.54 | 106,425 | 19,519,340 | |
2009-01-02 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 22,190 | 3,935,661 | 0.57 | 8.87 | 196,825 | 34,909,313 | |
2009-01-02 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 12,810 | 2,273,175 | 0.57 | 8.87 | 113,625 | 20,163,062 | |
2008-12-31 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 63,401 | 3,913,471 | 1.65 | 8.47 | 537,006 | 33,147,099 | |
2008-12-31 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 36,599 | 2,260,365 | 1.65 | 8.47 | 309,994 | 19,145,292 | |
2008-12-31 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 5,326 | 3,850,070 | 0.14 | 8.47 | 45,111 | 32,610,093 | |
2008-12-31 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 3,074 | 2,223,766 | 0.14 | 8.47 | 26,037 | 18,835,298 | |
2008-12-31 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 126,800 | 3,844,744 | 3.41 | 8.52 | 1,080,336 | 32,757,219 | |
2008-12-31 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 73,200 | 2,220,692 | 3.41 | 8.52 | 623,664 | 18,920,296 | |
2008-12-24 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 381 | 3,717,944 | 0.01 | 8.54 | 3,254 | 31,751,242 | |
2008-12-24 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 219 | 2,147,492 | 0.01 | 8.54 | 1,870 | 18,339,582 | |
2008-12-24 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 3,424 | 3,717,563 | 0.09 | 8.33 | 28,522 | 30,967,300 | |
2008-12-24 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 1,976 | 2,147,273 | 0.09 | 8.33 | 16,460 | 17,886,784 | |
2008-12-24 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 57,061 | 3,714,139 | 1.56 | 8.40 | 479,312 | 31,198,768 | |
2008-12-24 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 32,939 | 2,145,297 | 1.56 | 8.40 | 276,688 | 18,020,495 | |
2008-12-24 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 28,471 | 3,657,078 | 0.78 | 8.54 | 243,142 | 31,231,446 | |
2008-12-24 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 16,435 | 2,112,358 | 0.78 | 8.54 | 140,355 | 18,039,537 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 54,409 | 3,628,607 | 1.52 | 8.48 | 461,388 | 30,770,587 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 31,409 | 2,095,523 | 1.52 | 8.48 | 266,348 | 17,770,035 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 9,570 | 3,574,198 | 0.27 | 8.53 | 81,632 | 30,487,909 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 5,524 | 2,064,514 | 0.27 | 8.53 | 47,120 | 17,610,304 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 20,289 | 3,564,628 | 0.57 | 8.47 | 171,848 | 30,192,399 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 11,711 | 2,058,990 | 0.57 | 8.47 | 99,192 | 17,439,645 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 33,308 | 3,544,339 | 0.95 | 8.52 | 283,784 | 30,197,768 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 19,227 | 2,047,279 | 0.95 | 8.52 | 163,814 | 17,442,817 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 10,588 | 3,511,031 | 0.30 | 8.04 | 85,128 | 28,228,689 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 6,112 | 2,028,052 | 0.30 | 8.04 | 49,140 | 16,305,538 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 135,009 | 3,500,443 | 4.01 | 7.78 | 1,050,370 | 27,233,447 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 77,938 | 2,021,940 | 4.01 | 7.78 | 606,358 | 15,730,693 | |
2008-12-05 | 3 | NURO |
NeuroMetrix, Inc.
Common Stock |
650,085 | ||||||||
2008-12-05 | 3 | NURO |
NeuroMetrix, Inc.
Common Stock |
1,194,915 | ||||||||
2008-11-21 | 3 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
1,944,002 | ||||||||
2008-11-21 | 3 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
3,365,434 | ||||||||
2008-11-20 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -131,836 | 881,743 | -13.01 | 0.24 | -31,641 | 211,618 | |
2008-11-20 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -56,957 | 503,348 | -10.17 | 0.24 | -13,670 | 120,804 | |
2008-11-20 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -128,800 | 1,013,579 | -11.27 | 0.26 | -33,488 | 263,531 | |
2008-11-20 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -71,200 | 560,305 | -11.27 | 0.26 | -18,512 | 145,679 | |
2008-11-20 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -34,431 | 1,142,379 | -2.93 | 0.44 | -15,150 | 502,647 | |
2008-11-20 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -19,033 | 631,505 | -2.93 | 0.44 | -8,375 | 277,862 | |
2008-11-20 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -644 | 1,176,810 | -0.05 | 0.56 | -361 | 659,014 | |
2008-11-20 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -356 | 650,538 | -0.05 | 0.56 | -199 | 364,301 | |
2008-11-14 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -23,378 | 1,177,454 | -1.95 | 0.49 | -11,455 | 576,952 | |
2008-11-14 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -12,922 | 650,894 | -1.95 | 0.49 | -6,332 | 318,938 | |
2008-11-14 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -85,865 | 1,200,832 | -6.67 | 0.48 | -41,215 | 576,399 | |
2008-11-14 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -47,465 | 663,816 | -6.67 | 0.48 | -22,783 | 318,632 | |
2008-11-14 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -82,819 | 1,286,697 | -6.05 | 0.50 | -41,410 | 643,348 | |
2008-11-14 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -45,781 | 711,281 | -6.05 | 0.50 | -22,890 | 355,640 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -276,493 | 0 | -100.00 | 0.24 | -66,358 | ||
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -56,742 | 276,493 | -17.03 | 0.22 | -12,636 | 61,575 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -533,176 | 333,235 | -61.54 | 0.27 | -141,771 | 88,607 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -138,370 | 0 | -100.00 | 0.24 | -33,209 | ||
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -28,395 | 138,370 | -17.03 | 0.22 | -6,324 | 30,815 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -266,824 | 166,765 | -61.54 | 0.27 | -70,949 | 44,343 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -195,563 | 0 | -100.00 | 0.24 | -47,228 | ||
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -225,156 | 195,563 | -53.52 | 0.23 | -50,930 | 44,236 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -317,000 | 420,719 | -42.97 | 0.24 | -75,858 | 100,678 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -41,123 | 737,719 | -5.28 | 0.23 | -9,339 | 167,536 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -95,100 | 778,842 | -10.88 | 0.28 | -26,580 | 217,686 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -63,400 | 873,942 | -6.76 | 0.25 | -15,850 | 218,486 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -96,075 | 937,342 | -9.30 | 0.25 | -23,961 | 233,773 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -1,001,720 | 1,033,417 | -49.22 | 0.26 | -257,342 | 265,485 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -125,000 | 0 | -100.00 | 0.24 | -30,625 | ||
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -329,437 | 125,000 | -72.49 | 0.24 | -79,559 | 30,188 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -129,981 | 454,437 | -22.24 | 0.23 | -29,402 | 102,794 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -183,000 | 584,418 | -23.85 | 0.24 | -43,792 | 139,851 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -23,740 | 767,418 | -3.00 | 0.23 | -5,391 | 174,281 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -54,900 | 791,158 | -6.49 | 0.28 | -15,345 | 221,129 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -36,600 | 846,058 | -4.15 | 0.25 | -9,150 | 211,514 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -55,463 | 882,658 | -5.91 | 0.25 | -13,832 | 220,135 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -578,280 | 938,121 | -38.14 | 0.26 | -148,560 | 241,003 | |
2008-10-21 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Call Options |
S - Sale | -323,900 | 0 | -100.00 | ||||
2008-10-21 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Call Options |
S - Sale | -178,100 | 0 | -100.00 | ||||
2008-10-21 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Call Options |
J - Other | -460,400 | 0 | -100.00 | ||||
2008-10-21 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Call Options |
J - Other | -264,600 | 0 | -100.00 | ||||
2008-10-14 | 3 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
1,665,842 | ||||||||
2008-10-14 | 3 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
2,883,594 | ||||||||
2008-06-30 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 105,300 | 105,300 | |||||
2008-06-30 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 61,300 | 61,300 | |||||
2008-06-30 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 519,200 | 519,200 | |||||
2008-06-30 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 314,200 | 314,200 | |||||
2008-03-14 | 3 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
757,062 | ||||||||
2008-03-14 | 3 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
1,369,516 | ||||||||
2007-11-01 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 136,890 | 136,890 | |||||
2007-11-01 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 79,960 | 79,960 | |||||
2007-11-01 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 674,960 | 674,960 | |||||
2007-11-01 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 408,460 | 408,460 | |||||
2007-10-23 |
|
4 | ARNA |
ARENA PHARMACEUTICALS INC
Common Stock |
S - Sale | -15,875 | 3,238,908 | -0.49 | 10.51 | -166,805 | 34,032,502 | |
2007-10-23 |
|
4 | ARNA |
ARENA PHARMACEUTICALS INC
Common Stock |
S - Sale | -9,125 | 1,861,735 | -0.49 | 10.51 | -95,880 | 19,561,994 | |
2007-10-23 | 3 | ARNA |
ARENA PHARMACEUTICALS INC
Common Stock |
1,870,860 | ||||||||
2007-10-23 | 3 | ARNA |
ARENA PHARMACEUTICALS INC
Common Stock |
3,254,783 | ||||||||
2007-07-23 |
|
4/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 131,625 | 131,625 | |||||
2007-07-23 |
|
4/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 76,625 | 76,625 | |||||
2007-07-23 |
|
4/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 649,000 | 649,000 | |||||
2007-07-23 |
|
4/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 392,750 | 392,750 | |||||
2007-07-20 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 131,625 | 131,625 | |||||
2007-07-20 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 76,625 | 76,625 | |||||
2007-07-20 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 649,000 | 649,000 | |||||
2007-07-20 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 392,750 | 392,750 | |||||
2006-10-06 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 376,185 | 2,035,137 | 22.68 | 4.40 | 1,655,214 | 8,954,603 | |
2006-10-06 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 257,122 | 1,516,401 | 20.42 | 4.40 | 1,131,337 | 6,672,164 | |
2006-10-06 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 105,142 | 433,589 | 32.01 | 4.40 | 462,625 | 1,907,792 | |
2006-10-06 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 211,551 | 866,411 | 32.30 | 4.40 | 930,824 | 3,812,208 | |
2006-05-17 |
|
4/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 24,100 | 328,447 | 7.92 | 5.50 | 132,543 | 1,806,360 | |
2006-05-15 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 24,100 | 327,447 | 7.94 | 5.50 | 132,543 | 1,800,860 | |
2006-05-15 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 63,565 | 654,860 | 10.75 | 5.50 | 349,588 | 3,601,534 | |
2006-05-15 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 10,246 | 591,295 | 1.76 | 5.50 | 56,345 | 3,251,649 | |
2006-05-15 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 3,226 | 581,049 | 0.56 | 5.12 | 16,501 | 2,972,066 | |
2006-05-15 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 1,602 | 304,347 | 0.53 | 5.12 | 8,194 | 1,556,735 | |
2006-05-02 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 11,200 | 577,823 | 1.98 | 5.71 | 63,945 | 3,299,023 | |
2006-05-02 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 200 | 302,745 | 0.07 | 5.71 | 1,142 | 1,728,492 | |
2006-05-02 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 5,211 | 566,623 | 0.93 | 5.72 | 29,785 | 3,238,704 | |
2006-05-02 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 2,589 | 302,545 | 0.86 | 5.72 | 14,798 | 1,729,287 | |
2006-05-02 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 28,701 | 1,658,952 | 1.76 | 5.50 | 157,856 | 9,124,236 | |
2006-05-02 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 21,299 | 1,259,279 | 1.72 | 5.50 | 117,144 | 6,926,034 | |
2006-04-24 |
|
4/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 1,549 | 540,673 | 0.29 | 6.02 | 9,319 | 3,252,851 | |
2006-04-24 |
|
4/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 768 | 289,650 | 0.27 | 6.02 | 4,621 | 1,742,621 | |
2006-04-24 |
|
4/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 13,180 | 1,566,513 | 0.85 | 6.02 | 79,295 | 9,424,612 | |
2006-04-24 |
|
4/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 9,779 | 1,190,678 | 0.83 | 6.02 | 58,833 | 7,163,476 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 12,065 | 561,412 | 2.20 | 5.55 | 66,964 | 3,116,005 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 5,996 | 299,956 | 2.04 | 5.55 | 33,280 | 1,664,846 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 31,102 | 1,630,251 | 1.94 | 5.55 | 172,625 | 9,048,382 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 23,082 | 1,237,980 | 1.90 | 5.55 | 128,112 | 6,871,160 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 6,680 | 549,347 | 1.23 | 5.43 | 36,297 | 2,984,987 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 3,320 | 293,960 | 1.14 | 5.43 | 18,040 | 1,597,290 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 17,220 | 1,599,149 | 1.09 | 5.43 | 93,568 | 8,689,296 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 12,780 | 1,214,898 | 1.06 | 5.43 | 69,443 | 6,601,391 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 1,994 | 542,667 | 0.37 | 5.48 | 10,923 | 2,972,784 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 990 | 290,640 | 0.34 | 5.48 | 5,423 | 1,592,155 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 15,416 | 1,581,929 | 0.98 | 5.48 | 84,450 | 8,665,965 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 11,440 | 1,202,118 | 0.96 | 5.48 | 62,669 | 6,585,323 | |
2006-04-05 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 13,180 | 552,304 | 2.44 | 6.02 | 79,295 | 3,322,827 | |
2006-04-05 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 9,779 | 298,661 | 3.39 | 6.02 | 58,833 | 1,796,834 | |
2006-04-05 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 1,549 | 1,554,882 | 0.10 | 6.02 | 9,319 | 9,354,637 | |
2006-04-05 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 768 | 1,181,667 | 0.07 | 6.02 | 4,621 | 7,109,263 | |
2006-04-05 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 1,761 | 539,124 | 0.33 | 6.03 | 10,626 | 3,253,182 | |
2006-04-05 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 874 | 288,882 | 0.30 | 6.03 | 5,274 | 1,743,172 | |
2006-04-05 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 26,678 | 1,553,333 | 1.75 | 6.03 | 160,980 | 9,373,122 | |
2006-04-05 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 19,796 | 1,180,899 | 1.70 | 6.03 | 119,453 | 7,125,781 | |
2006-04-05 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 32,132 | 537,363 | 6.36 | 6.03 | 193,804 | 3,241,105 | |
2006-04-05 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 15,968 | 288,008 | 5.87 | 6.03 | 96,311 | 1,737,120 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 1,122 | 505,231 | 0.22 | 5.91 | 6,630 | 2,985,663 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 603 | 272,040 | 0.22 | 5.91 | 3,563 | 1,607,620 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 7,248 | 1,526,655 | 0.48 | 5.91 | 42,832 | 9,021,768 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 5,511 | 1,161,103 | 0.48 | 5.91 | 32,567 | 6,861,538 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 2,938 | 504,109 | 0.59 | 6.02 | 17,694 | 3,035,946 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 1,581 | 271,437 | 0.59 | 6.02 | 9,521 | 1,634,702 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 18,981 | 1,519,407 | 1.27 | 6.02 | 114,311 | 9,150,477 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 14,434 | 1,155,592 | 1.26 | 6.02 | 86,927 | 6,959,437 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 5,281 | 501,171 | 1.06 | 5.95 | 31,439 | 2,983,621 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 2,843 | 269,856 | 1.06 | 5.95 | 16,925 | 1,606,534 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 34,119 | 1,500,426 | 2.33 | 5.95 | 203,121 | 8,932,486 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 25,948 | 1,141,158 | 2.33 | 5.95 | 154,476 | 6,793,656 | |
2006-03-09 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 1,185 | 495,890 | 0.24 | 6.03 | 7,144 | 2,989,423 | |
2006-03-09 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 638 | 267,013 | 0.24 | 6.03 | 3,846 | 1,609,661 | |
2006-03-09 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 7,655 | 1,466,307 | 0.52 | 6.03 | 46,147 | 8,839,485 | |
2006-03-09 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 5,822 | 1,115,210 | 0.52 | 6.03 | 35,097 | 6,722,932 | |
2006-03-09 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 11,375 | 494,705 | 2.35 | 6.00 | 68,250 | 2,968,230 | |
2006-03-09 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 6,125 | 266,375 | 2.35 | 6.00 | 36,750 | 1,598,250 | |
2006-03-07 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 9,840 | 483,330 | 2.08 | 5.90 | 58,068 | 2,852,227 | |
2006-03-07 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 5,295 | 260,250 | 2.08 | 5.90 | 31,247 | 1,535,787 | |
2006-03-07 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 59,128 | 1,458,652 | 4.22 | 5.90 | 348,926 | 8,607,797 | |
2006-03-07 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 44,967 | 1,109,388 | 4.22 | 5.90 | 265,359 | 6,546,720 | |
2006-03-07 | 3/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
993,599 | ||||||||
2006-03-07 | 3/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
245,000 | ||||||||
2006-03-07 | 3/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
1,306,401 | ||||||||
2006-03-07 | 3/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
455,000 |